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Abstract: Interleukin-1￿ (IL-1￿) ist ein entzündungsförderndes Zytokin, welches eine Schlüsselrolle in
akuten und chronischen Entzündungen spielt. Insbesondere seine Rolle in der Pathogenese der Au-
toinflammation machen IL-1￿ zu einem idealen Ziel um die schwere verschiedenartigster Erkrankungen
schnell zu reduzieren. IL-1￿ wird in seiner biologisch inaktiven Pro-Form produziert und um aktiviert und
sekretiert zu werden muss es durch einen Multiproteinkomplex, das sogenannte Inflammasom, geschnitten
werden. Daher spielt die Aktivität des Inflammasoms eine wichtige Rolle in vielen pathologischen und
physiologischen Prozessen. Der Hauptteil meiner Doktorarbeit befasst sich mit der Identifikation der
Mechanismen, welche das Inflammasom regulieren könnten. Unter den verschiedenen zur Zeit bekannten
Inflammasomen ist das am meisten studierte das NLRP3 Inflammasom. Es konnte gezeigt werden, dass
viele verschiedene Stimulantien mit unterschiedlichen Eigenschaften (Umweltstress, pathogene Partikel,
pathogen-assoziierte Strukturen, gefahr- induzierende Metabolite, gefahr-induzierende Strukturen) das
NLRP3 Inflammasom aktivieren können. Daher muss der Zelle ein gemeinsamer Pfad zugrunde liegen,
welcher die unterschiedlichen Stimuli in einen einzelnen Pfad bündelt, welcher wiederum zur Aktivierung
des Inflammasoms führt. In der vorliegenden Arbeit konnten wir zeigen, das Mitogen-Associated Protein
Kinasen (MAPKn) aktiviert werden nachdem Immun- und Nicht-Immunzellen verschiedensten Stimula-
toren des Inflammasoms ausgesetzt wurden und das diese Stimulatoren beteiligt sind an der Schädigung
der Mitochondrien und dem Auslaufen mitochondrialer DNA in das Zytosol, was im Anschluss zur Ak-
tivierung des NLRP3 Inflammasoms führt. Dieser Prozess ist auf die zwei BCL-2 Familienmitglieder,
BAD und BCL-XL angewiesen und wird durch MAPK und Phosphatase-1 abgestimmt. Acne vulgaris
ist eine der am Häufigsten auftretenden Hauterkrankung welche Rund 80% der Bevölkerung irgendwann
in ihrem Leben betrifft. Es ist eine multifaktorielle Erkrankung, welche das Potential in sich birgt sich in
einer schweren Form zu manifestieren. In dieser Doktorarbeit zeigen wir, dass Propionibacterium acnes,
ein Bakterium welches sich in entzündeten Aknelesionen (Pusteln) findet, fähig ist, nach Internalisierung,
das NLRP3 Inflammasom zu aktivieren, was zur Freisetzung von cathepsin B-abhängigen reaktiven Sauer-
stoffradikalen führt. Wir konnten weiter zeigen, dass das NLRP3 Inflammasom in myeloiden Zellen eine
wichtige Rolle in einem in vivo Modell spielt und dass das gezielte Ansteuern des IL-1￿ ein effektiver
Ansatz ist neutrophile Entzündungsreaktionen zu hemmen. Kontakt-Überempfindlichkeit ist ebenfalls
eine häufige Hauterkrankung in welcher IL-1￿ eine wichtige Rolle spielt. Kontaktallergene sind chemische
kleine organische Moleküle welche an körpereigene Proteine binden und so ein Neo-Antigen generieren,
in einem Prozess welcher als Haptenbildung bezeichnet wird. Haptene, wie Dinitrofluorobenzen (DNFB)
und Dinitrothiocyanobenzen (DNTB) präsentieren kreuzreaktive Antigene, welche sensibilisierende oder
tolerierende T-Zellantworten hervorrufen. In dieser Doktorarbeit konnten wir im Mausmodell zeigen,
dass das NLRP3 Inflammasom zur Sensibilisierung gegen DNTB und zur Tolerierung von DNFB führen
kann, was den ersten Beweis anführt, dass das Inflammasom eine Antigen-spezifische erworbene Im-
munantwort definieren kann und neue Strategien zur Beeinflussung von T-Zellantworten im Lebenden
andeutet. Zusammenfassend geben die Ergebnisse dieser Doktorarbeit einen Einblick in die Regelung
der Aktivierung des Inflammasoms und die daraus resultierende IL-1￿ Ausschüttung durch MAPKn und
enträtseln die entscheidende Rolle des NLRP3 Inflammasoms in der Pathogenese der Acne vulgaris und
der Entstehung der Kontakt-Überempfindlichkeit. Interleukin-1￿ (IL-1￿) is a key pro-inflammatory cy-
tokine associated to acute and chronic inflammation. It plays a crucial role in the pathogenesis of
auto-inflammatory diseases and targeting IL-1￿ is an efficient way to obtain a sustained and rapid reduc-
tion in the severity of several disorders. IL-1￿ is synthetized in a pro-form, which is biologically inactive,
and in order to become active and secreted needs to be cleaved by cytosolic multiprotein complexes
called inflammasomes. Therefore, regulation of inflammasome activity is crucial in many pathological
and physiological conditions. In the main part of this thesis, we looked for the possible mechanisms
that could be responsible for the regulation of the inflammasome. Among the different inflammasomes
known to date, the most studied one is NLRP3 inflammasome. Many different stimuli of different na-
tures (environmental stresses, pathogen particles, pathogen-associated molecular patterns, metabolites
considered as danger signals, danger-associated molecular patterns) have been shown to activate the
NLRP3 inflammasome. Therefore its hypothesized that there may be a common pathway used by the
cell to centralize such diverse stimuli to a unique pathway leading to inflammasome activation. In the
present work, we could demonstrate that Mitogen- Associated Protein Kinases (MAPKs) become active
upon stimulation of immune and non-immune cells with several inflammasome activators and that they
are involved in mitochondria damage and leakage of mitochondrial DNA to the cytosol, subsequently
activating the NLRP3 inflammasome. This process is dependent on two BCL-2 family members, namely
BAD and BCL- XL and modulated by MAPK phosphatase-1. Acne vulgaris is the most common skin
disease, affecting around 80% of the population at some time in their lives. It is a multifactorial in-
flammatory disease, which can potentially manifest in very severe forms. In this thesis, wehow that
Propionibacterium acnes (P.acnes), a bacterium found in inflammatory acne lesions (pustules), is able to
activate the NLRP3 inflammasome upon its internalization, leading to reactive oxygen species generation
and depending on cathepsin B. We could also show that NRLP3 inflammasome in myeloid cells plays a
key role in an in vivo model, and that targeting IL-1￿ is an effective approach to prevent neutrophilic
inflammation induced by P.acnes. Contact hypersensitivity is also a common skin disorder in which IL-1￿
was shown to play a role. Contact allergens are chemically reactive small organic molecules binding to
self-proteins to generate immunogenic neo- antigens, through a process termed haptenization. Haptens
such as dinitrofluorobenzene (DNFB) and dinitrothiocyanobenzene (DNTB) provide cross-reactive anti-
gens driving opposite, sensitizing versus tolerizing, T cell responses. In this thesis we show that, in mice,
the NLRP3 inflammasome can turn DNTB into a sensitizer and DNFB into a tolerizer, providing the
first evidence that the inflammasome can define the type of adaptive immune response elicited by an
antigen, and hint at new strategies to modulate T cell responses in vivo. Taken together, the results of
this thesis provide insight to the regulation of inflammasome activation and subsequent IL-1￿ secretion
by MAPK, they also unravel the crucial role of the NLRP3 inflammasome in the pathogenesis of Acne
and in the process of sensitization of molecules in Contact Hypersensitivity.
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Zusammenfassung 
 
 
 
Interleukin-1β (IL-1β) ist ein entzündungsförderndes Zytokin, welches 
eine Schlüsselrolle in akuten und chronischen Entzündungen spielt. 
Insbesondere seine Rolle in der Pathogenese der Autoinflammation machen 
IL-1β zu einem idealen Ziel um die schwere verschiedenartigster 
Erkrankungen schnell zu reduzieren. IL-1β wird in seiner biologisch inaktiven 
Pro-Form produziert und um aktiviert und sekretiert zu werden muss es durch 
einen Multiproteinkomplex, das sogenannte Inflammasom, geschnitten 
werden. Daher spielt die Aktivität des Inflammasoms eine wichtige Rolle in 
vielen pathologischen und physiologischen Prozessen. 
  
Der Hauptteil meiner Doktorarbeit befasst sich mit der Identifikation der 
Mechanismen, welche das Inflammasom regulieren könnten. Unter den 
verschiedenen zur Zeit bekannten Inflammasomen ist das am meisten 
studierte das NLRP3 Inflammasom. Es konnte gezeigt werden, dass viele 
verschiedene Stimulantien mit unterschiedlichen Eigenschaften 
(Umweltstress, pathogene Partikel, pathogen-assoziierte Strukturen, gefahr-
induzierende Metabolite, gefahr-induzierende Strukturen) das NLRP3 
Inflammasom aktivieren können. Daher muss der Zelle ein gemeinsamer Pfad 
zugrunde liegen, welcher die unterschiedlichen Stimuli in einen einzelnen 
Pfad bündelt, welcher wiederum zur Aktivierung des Inflammasoms führt. In 
der vorliegenden Arbeit konnten wir zeigen, das Mitogen-Associated Protein 
Kinasen (MAPKn) aktiviert werden nachdem Immun- und Nicht-Immunzellen 
verschiedensten Stimulatoren des Inflammasoms ausgesetzt wurden und das  
diese Stimulatoren beteiligt sind an der Schädigung der Mitochondrien und 
dem Auslaufen mitochondrialer DNA in das Zytosol, was im Anschluss zur 
Aktivierung des NLRP3 Inflammasoms führt. Dieser Prozess ist auf die zwei 
BCL-2 Familienmitglieder, BAD und BCL-XL angewiesen und wird durch 
MAPK und Phosphatase-1 abgestimmt. 
  
iv 
Acne vulgaris ist eine der am Häufigsten auftretenden Hauterkrankung 
welche Rund 80% der Bevölkerung irgendwann in ihrem Leben betrifft. Es ist 
eine multifaktorielle Erkrankung, welche das Potential in sich birgt sich in 
einer schweren Form zu manifestieren. In dieser Doktorarbeit zeigen wir, dass 
Propionibacterium acnes, ein Bakterium welches sich in entzündeten 
Aknelesionen (Pusteln) findet, fähig ist, nach Internalisierung, das NLRP3 
Inflammasom zu aktivieren, was zur Freisetzung von cathepsin B-abhängigen 
reaktiven Sauerstoffradikalen führt. Wir konnten weiter zeigen, dass das 
NLRP3 Inflammasom in myeloiden Zellen eine wichtige Rolle in einem in vivo 
Modell spielt und dass das gezielte Ansteuern des IL-1β ein effektiver Ansatz 
ist neutrophile Entzündungsreaktionen zu hemmen. 
  
Kontakt-Überempfindlichkeit ist ebenfalls eine häufige Hauterkrankung 
in welcher IL-1β eine wichtige Rolle spielt. Kontaktallergene sind chemische 
kleine organische Moleküle welche an körpereigene Proteine binden und so 
ein Neo-Antigen generieren, in einem Prozess welcher als Haptenbildung 
bezeichnet wird. Haptene, wie Dinitrofluorobenzen (DNFB) und 
Dinitrothiocyanobenzen (DNTB) präsentieren kreuzreaktive Antigene, welche 
sensibilisierende oder tolerierende T-Zellantworten hervorrufen. In dieser 
Doktorarbeit konnten wir im Mausmodell zeigen, dass das NLRP3 
Inflammasom zur Sensibilisierung gegen DNTB und zur Tolerierung von 
DNFB führen kann, was den ersten Beweis anführt, dass das Inflammasom 
eine Antigen-spezifische erworbene Immunantwort definieren kann und neue 
Strategien zur Beeinflussung von T-Zellantworten im Lebenden andeutet. 
  
Zusammenfassend geben die Ergebnisse dieser Doktorarbeit einen 
Einblick in die Regelung der Aktivierung des Inflammasoms und die daraus 
resultierende IL-1β Ausschüttung durch MAPKn und enträtseln die 
entscheidende Rolle des NLRP3 Inflammasoms in der Pathogenese der Acne 
vulgaris und der Entstehung der Kontakt-Überempfindlichkeit. 
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Summary 
 
 
 
Interleukin-1β (IL-1β) is a key pro-inflammatory cytokine associated to 
acute and chronic inflammation. It plays a crucial role in the pathogenesis of 
auto-inflammatory diseases and targeting IL-1β is an efficient way to obtain a 
sustained and rapid reduction in the severity of several disorders.  IL-1β is 
synthetized in a pro-form, which is biologically inactive, and in order to 
become active and secreted needs to be cleaved by cytosolic multiprotein 
complexes called inflammasomes. Therefore, regulation of inflammasome 
activity is crucial in many pathological and physiological conditions. 
 
In the main part of this thesis, we looked for the possible mechanisms 
that could be responsible for the regulation of the inflammasome. Among the 
different inflammasomes known to date, the most studied one is NLRP3 
inflammasome. Many different stimuli of different natures (environmental 
stresses, pathogen particles, pathogen-associated molecular patterns, 
metabolites considered as danger signals, danger-associated molecular 
patterns) have been shown to activate the NLRP3 inflammasome.  Therefore 
its hypothesized that there may be a common pathway used by the cell to 
centralize such diverse stimuli to a unique pathway leading to inflammasome 
activation. In the present work, we could demonstrate that Mitogen-
Associated Protein Kinases (MAPKs) become active upon stimulation of 
immune and non-immune cells with several inflammasome activators and that 
they are involved in mitochondria damage and leakage of mitochondrial DNA 
to the cytosol, subsequently activating the NLRP3 inflammasome. This 
process is dependent on two BCL-2 family members, namely BAD and BCL-
XL and modulated by MAPK phosphatase-1. 
 
Acne vulgaris is the most common skin disease, affecting around 80% 
of the population at some time in their lives.  It is a multifactorial inflammatory 
disease, which can potentially manifest in very severe forms. In this thesis, we 
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show that Propionibacterium acnes (P.acnes), a bacterium found in 
inflammatory acne lesions (pustules), is able to activate the NLRP3 
inflammasome upon its internalization, leading to reactive oxygen species 
generation and depending on cathepsin B. We could also show that NRLP3 
inflammasome in myeloid cells plays a key role in an in vivo model, and that 
targeting IL-1β is an effective approach to prevent neutrophilic inflammation 
induced by P.acnes. 
 
Contact hypersensitivity is also a common skin disorder in which IL-1β 
was shown to play a role. Contact allergens are chemically reactive small 
organic molecules binding to self-proteins to generate immunogenic neo-
antigens, through a process termed haptenization. Haptens such as 
dinitrofluorobenzene (DNFB) and dinitrothiocyanobenzene (DNTB) provide 
cross-reactive antigens driving opposite, sensitizing versus tolerizing, T cell 
responses. In this thesis we show that, in mice, the NLRP3 inflammasome 
can turn DNTB into a sensitizer and DNFB into a tolerizer, providing the first 
evidence that the inflammasome can define the type of adaptive immune 
response elicited by an antigen, and hint at new strategies to modulate T cell 
responses in vivo.  
 
Taken together, the results of this thesis provide insight to the 
regulation of inflammasome activation and subsequent IL-1β secretion by 
MAPK, they also unravel the crucial role of the NLRP3 inflammasome in the 
pathogenesis of Acne and in the process of sensitization of molecules in 
Contact Hypersensitivity.  
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Chapter  1  
 
Introduction 
 
  
 
1.1  Interleukin  1β 
 
Interleukin 1 (IL-1), the first discovered cytokine, by Gery et al. in 
1972[1] was, at that time, called lymphocyte activating factor (LAF) due to its 
lymphocyte mitogen activity. Since then it has been shown to have several 
other pro-inflammatory properties, as fever, hypotension, tachycardia, 
hyperinsulinemia, neutrophilia, increased antibody production, inhibition of 
tolerance to protein antigens[2] and dendritic cell maturation[3]. The cytokine 
receptor for IL-1 was characterized; sister cytokines were discovered (IL-1α 
and β, IL-1RA, IL-18) and a whole mechanism of sensing danger by innate 
immunity (inflammasomes) was unravel.  
The IL-1 family consists of several cytokines, which bind to receptors 
sharing homology with Toll-like receptors (TLRs), and include 10 members 
(IL-1R1-10) (Figure 1).  
IL-1α and IL-1β share 27% homology, are structurally quite similar, and 
are biologically equivalent, with very minor functional differences. IL-1s are 
pleiotropic factors that act in local and systemic inflammation. 
IL-1 cytokines exert their biological functions through binding to their 
receptors. The receptor complex for IL-1α and IL-1β consists of IL-1R1 and 
the IL-1R accessory protein (IL-1R-AcP)[4]. Upon dimerization, the complex 
activates an intracellular signaling cascade through the toll-domains in the 
cytoplasmic part, which results in activation of NF-kB and to a certain extent 
Mitogen Activated Protein (MAP) kinases. 
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                  adapted from Allan et al., 2005[5] 
Figure 1. The interleukin-1 family. The various members of the interleukin-1 (IL-1) family and 
their receptors are shown. Possible receptor–ligand interactions that initiate downstream signaling are 
also indicated. IL-1F, IL-1 family; IL-1R1, type I IL-1 receptor; IL-1R2, type II IL-1 receptor; IL-1RA, IL-1-
receptor antagonist; IL-1RAcP, IL-1-receptor accessory protein; IL-1RAPL1, IL-1-receptor accessory-
protein-like 1; IL-1RRP2, IL-1-receptor-related protein 2; IL-18R, IL-18 receptor; IL-18RAcP, IL-18-
receptor accessory protein; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor-κB; SIGIRR, 
single immunoglobulin IL-1-receptor-related molecule; TIGIRR, three-immunoglobulin-domain-
containing IL-1-receptor-related molecule. 
 
These events lead to expression of genes encoding mainly pro-
inflammatory proteins such as IL-6, IL-8 and TNF-α  (figure 2). The antagonist 
of IL-1 is IL-1 receptor antagonist (IL-1 Ra), that can also bind to IL-1R1 but 
lacks the ability to recruit IL-1R AcP. Therefore, IL-1 Ra prevents IL-1 
signaling by competing with IL-1α and IL-1β. The second IL-1 receptor (IL-
1R2) lacks an intracellular domain for signal transduction and is not able to 
dimerize with IL-1R AcP, therefore acting as a decoy receptor. Furthermore, a 
truncated soluble form of this receptor (sIL-1R2) can be secreted by cells. sIL-
1R2 also traps IL-1 and IL-1R AcP molecules. 
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3 
 
           adapted from Murphy et al., 
2000[6] 
Figure 2. IL-1 induces the transcription of genes involved in inflammation via activation of the 
transcription factor NF-kB. The membrane-bound IL-1R type 1 can bind either IL-1α or β and, when 
complexed to the receptor accessory protein, will initiate the signal transduction cascade that ultimately 
results in stimulation of transcription of adhesion molecules, cytokines, and pro-inflammatory genes. 
This complex recruits the adaptor molecule MyD88 that binds to the IRAKs. The IRAKs bind to another 
adaptor molecule, TNF receptor associated factor 6, which associates with TAK1, the kinase that 
phosphorylates the NF-kB-inducing kinase. NF-kB-inducing kinase activates IKK, which can 
phosphorylate IkB, causing its rapid degradation. NF-kB is then free to migrate into the nucleus, where it 
binds to specific sequences (kB sites) in the promoter region of multiple inflammatory genes. 
 
1.2  Regulation of IL-1 production 
Since IL-1 is such a potent and important cytokine it is not surprising 
that the generation of IL-1 activity is tightly regulated at different levels.  
Evidence suggests that the expression of IL-1α although regulated, exists to 
some extent at a constitutive level, whereas the expression of IL-1β is only 
detectable in most cell types upon stimulation [7, 8]. Expression of IL-1a and b 
is induced by activation of the transcription factor NF-ĸB, which can be 
induced by bacterial endotoxins, viruses, mitogens, antigens, cytokines like 
TNF-α, IFN-α, IFN-β and IFN-γ, as well by IL-1 itself. In addition, it has been 
shown that IL-1β mRNA can be very unstable [9, 10]. 
Both IL-1α and IL-1β are expressed as 31 kDa pro-molecules that lack 
a signal peptide for ER/Golgi-dependent secretion. IL-1α and IL-1β are 
4 
maturated by the protease caspase-1 [11], which is required to generate the 
active forms of the cytokines. Although extracellular pro-IL-1β can be cleaved 
after cell disruption by other proteases including elastase, cathepsin G, 
collagenase and protease 3, which are released at sites of inflammation [12, 
13] caspase-1 is the major intracellular activator of IL-1β. In contrast to proIL-
1β, proIL-1α is able to bind and activate IL-1RI although proteolysis of its 
prosequence can enhance its biological activity [14]. Therefore, cell lysis upon 
injury or trauma generates IL-1 activity due to passive release of proIL-1α, 
whereas passively released proIL-1β does not possess biological activity. 
Most secreted proteins contain a signal peptide at the amino terminus, 
which directs them through the classical endoplasmic reticulum/Golgi-
dependent secretion pathway to the extracellular space. In contrast, proIL-1α, 
proIL-1β and several other proteins are leaderless, thus lacking a signal 
peptide, and are secreted by a non-canonical pathway, called the 
unconventional protein secretion pathway [15]. The mechanism and 
regulation of unconventional secretion is only poorly understood but it has 
been recently demonstrated that caspase-1 activity is required for the 
secretion of leaderless proteins [16, 17].  
IL-1Ra blocks IL-1 activity. Although IL-1Ra, IL-1α and IL-1β have a 
similar affinity to IL-1RI, a large excess (100-1000) of IL-1Ra over IL-1 is 
required for efficient blockade of receptor signaling in vitro and in vivo [18]. 
The regulation of caspase-1 activity is done by inflammasomes, 
discussed later in this introduction.  
IL-1β plays a key role in rheumatoid arthritis, sepsis, diabetes, sunburn, 
contact hypersensitivity, graft-versus-host disease, anti-cancer response, 
adjuvant chemotherapy effectiveness, hypertension, diabetes, Alzheimer’s 
disease, and some auto-inflammatory diseases like Familial Mediterranean 
fever, Familial cold autoinflammatory syndrome (FCAS), Muckle-wells 
syndrome, Neonatal-onset multi-inflammatory disease (NOMID), Mevalonic 
aciduria, HyperIgD syndrome, Adult-onset Still’s disease, Schnitzler’s 
syndrome, Behcet’s syndrome, PAPA syndrome, CINCA and urate crytal 
arthritis (gout)[7, 19-29]. 
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Therefore, understanding more about IL-1β and its mechanisms of 
regulation, has a direct relevance for our understanding of these diseases and 
potentially for their management.  
 
1.3  The inflammasomes 
 
Despite the fact that IL-1 was the first cytokine discovered, the 
mechanism that leads to its secretion has only been relatively recently 
discovered. Named the inflammasomes and first discovered by Tschopp and 
colleagues[30] in 2002, the inflammasomes are high-molecular-weight protein 
complexes that are localized in the cytosol and serve as platforms for the 
recruitment and autoproteolytic activation of certain caspases, notably 
caspase-1 (Figure 3).  
 
 
 
 
           adapted from Von Motke et all, 2012  
Figure 3: Model of inflammasome activation. Cytosolic nucleotide-binding domain, leucine-rich 
repeat (NBD-LRR) proteins are maintained in an autoinhibited state until ligand recognition and ATP 
binding drive oligomerization via the NBD domain. Recruitment of CASP1 to form the inflammasome 
complex occurs directly via CARD-CARD interactions or indirectly via the adaptor ASC. Monomeric 
CASP1 is believed to be activated by proximity-induced autoproteolysis (autoprocessing), leading to 
downstream effector functions such as pyroptosis and processing of pro-IL-1β and pro-IL-18. 
Abbreviations: CARD, caspase activation and recruitment domain; PYD, PYRIN domain. 
 
 
Caspases 1, 4, and 5, along with caspase 11 and caspase 12 in the 
mouse, are called inflammatory caspases and are distinct from the caspases 
involved in the induction of apoptosis. Caspase-1 is the best characterized 
among inflammatory caspases and was first described as the protease 
required for the proteolytic cleavage of pro-IL-1β and pro-IL-18, resulting in 
their functional maturation and release[31, 32] .  
In the last few years, it has become clear that there are in fact multiple 
distinct inflammasomes, each of them is activated by a unique stimulus or a 
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group of stimuli that can include infectious agents as well as noninfectious 
stimuli. The formation of each inflammasome is dictated by a unique 
scaffolding protein (Figure 4). 
 
      adapted from Von Motke et all, 2012 
Figure 4. Inflammasome proteins and their domains. NBD-LRR family members can be 
categorized according to the unique domains they encode: 1. NLRP1: FIIND; 2. all other NLRP proteins: 
PYRIN domain (PYD);3. NLRC: CARD; 4. NAIP: BIR domains.5. AIM2 belongs to the PYHIN family of 
proteins and uses the HIN-200 domain for ligand recognition.6. NLRP10 is the only family member 
lacking an LRR domain. 7. ASC is an adaptor required by NLRP proteins for recruitment of CASP1. 8. 
Caspase-1 contains a CARD and a protease domain that autoprocesses into p10 and p20 subunits. 
CASP11 and CASP12 are additional inflammatory caspases in mice; CASP4 and CASP5 are additional 
inflammatory caspases in humans. 
 
Most of these scaffolding proteins contain a nucleotide-binding domain 
(NBD) and leucine-rich repeats (LRRs) and are members of the NBD-LRR 
(NLR) superfamily. The LRRs are believed to have two functions. First, LRRs 
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leads to a constitutively active NLR. Second, by analogy to the well-
characterized ligand binding function of LRR domains in Toll-like receptors 
(TLRs), the LRRs of NLRs are believed to mediate recognition of pathogen-
derived (or potentially self-derived) ligands. The NBD is believed to mediate 
the assembly of NLRs into an oligomerized state that is critical for the 
induction of downstream signaling. In NLRs, signaling is initiated by CARDs 
(caspase activation and recruitment domains) that can recruit Caspase-1 
directly or by PYRIN domains that recruit caspase-1 via the CARD-PYRIN-
containing adaptor protein ASC. Once recruited to an oligomerized 
inflammasome, caspase-1 is activated via dimerization and auto-proteolysis. 
Interestingly, non-NLR proteins such as PYRIN-HIN-200 (PYHIN) proteins 
have also been shown to mediate caspase-1 activation[32-36]. Although 
PYHIN proteins lack NBDs and LRRs, they may nevertheless exhibit the 
properties of auto-inhibition and ligand-induced oligomerization[37]. 
Four types of inflammasome complexes that are activated upon 
encounter with distinct types of DAMPs and/or PAMPs have been 
characterized. These are the Aim2, NLRP1, NLRP3 and NLRC4 
inflammasomes. The Aim2 inflammasome is activated by binding to viral and 
bacterial double-stranded DNA resulting from intracellular pathogens, the 
NLRP1 inflammasome by muramyl dipeptide, and NLRC4 inflammasome by 
flagellin [38]. The NLRP3 inflammasome is most likely the most important 
inflammasome since it assembles in response to a large variety of PAMPs 
and DAMPs, and its deficiency is already clearly associated with 
immunological dysfunction in mice as well as disease states in men. Since a 
direct interaction of any of these activators with NLRP3 could not be shown, 
indirect activation mechanisms have been suggested. Particulates such as 
asbestos or crystals such as gout-causing monosodium urate (MSU) or 
cholesterol are phagocytosed by macrophages [39, 40]. However, their 
clearance is not efficient and this results in lysosomal rupture, which, in turn, 
activates the NLRP3 inflammasome by an unknown mechanism perhaps 
involving cathepsins [40, 41]. As all NLRP3 activators induce the generation 
of reactive oxygen species (ROS), it has been reported that this ROS 
production triggers NLRP inflammasome activation [41]. Generation of ROS 
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induces the dissociation of thioredoxin from thioredoxin-interacting protein. 
Then the latter is able to bind NLRP3, which induces inflammasome activation 
[42]. The predominant source of ROS generated by danger signals is most 
likely the mitochondria, which also controls inflammasome activation via the 
release of mitochondrial DNA [43, 44]. 
 
It has become clear that inflammasomes not only have diverse 
mechanisms of activation but can also have diverse functions that extend 
beyond cytokine processing. Most notably, inflammasome activation is 
frequently associated with a rapid and lytic form of host cell suicide called 
pyroptosis[45]. Inflammasome activation plays a critical role in mediating host 
defense, but inappropriate or excessive inflammasome activation can also be 
detrimental and lead to pathological situations. Inflammasomes constitute a 
complex and surprisingly diverse set of cytosolic sensors that must be strictly 
regulated. 
 
 
1.4  MAPK kinases 
 
Mitogen-activated protein kinase (MAPK) signal transduction pathways 
are ubiquitous and highly evolutionarily conserved mechanisms of eukaryotic 
cell regulation. The multiple MAPK pathways present in all eukaryotic cells 
enable coordinated and integrated responses to diverse stimuli. These stimuli 
include hormones, growth factors, cytokines, agents that act through G 
protein-coupled receptors, transforming growth factor (TGF)-β-related agents 
that act through Serine-Threonine kinase receptors, pathogen-associated 
molecular patterns (PAMPs) and danger-associated molecular patterns 
(DAMPs) that recruit pattern recognition receptors (PRRs), and environmental 
stresses. MAPK pathways, once activated, exert major effects on cell 
physiology. MAPKs orchestrate gene transcription, protein biosynthesis, cell 
cycle control, apoptosis, and differentiation[46-54]. Their targets have 
important implications in organ development, innate and acquired immunity, 
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and diseases such as atherosclerosis, hypertension, tumorigenesis, and type 
2 diabetes [55]. 
Mammals express multiple MAPK pathways. The majority of these are, 
along with the nuclear factor-κB (NF-κB) pathway, activated by stress and 
inflammatory stimuli.  MAPK pathways consist principally of 3 distinguished 
pathways:  JNK, ERK and P38. An overview of MAPK pathways is shown in 
figure 5. 
 
 
    
         adapted from Hazzalin et al., 2002 
Figure 5. Mammalian MAPK cascades. Schematic representation of mammalian MAPK 
cascades and target substrates, including transcription factors that are involved in the regulation of fos 
and jun immediate-early (IE) genes. The four characterized MAPKs comprise the extracellular- signal 
regulated kinase/mitogen-activated protein kinase (ERK/MAPK), c-Jun amino-terminal kinase/stress-
activated protein kinase (JNK/SAPK), p38/reactivating kinase (RK)/p40/cytokine-suppressive anti-
inflammatory drug-binding protein (CSBP)/Mxi2 kinase and big MAPK (BMK/ERK5) subtypes. bFGF, 
basic fibroblast growth factor; EGF, epidermal growth factor; MEK, MAPK/ERK kinase; MKK/MAPKK, 
MAPK kinase; SKK, SAPK kinase; TPA, 12-O- tetradecanoylphorbol-13-acetate. 
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1.4.1 MAPK pathways in innate immunity and TLR responses 
 
Innate immunity represents the first line of defense against invading 
microbial pathogens. PRRs are known to have an important contribution in 
innate immune responses. PRRs include membrane-associated TLRs as well 
as cytosolic nucleotide oligomerization domain-leucine-rich repeat (NOD-
LRR) and RIG-like helicase (RLH) proteins. These receptors, upon 
engagement with agonists, recruit a variety of adaptor proteins, including 
myeloid differentiation factor-88 (MyD88) and Toll/IL-1 receptor (TIR)-domain-
containing adapter-inducing interferon-β (TRIF). [56-59]. 
 PRRs are trigered both by PAMPs (molecular moieties present on 
invading pathogens), and by DAMPs (molecules produced endogenously in 
conditions of physiological stress). DAMPs with known relevance to disease 
include oxidized LDL (oxLDL), relevant to atherosclerosis and crystalline uric 
acid, relevant to gout. Specific PAMPs and DAMPs recruit distinct groups of 
PRRs. Notably, LPS from Gram-negative bacteria recruits TLR4, and bacterial 
peptidoglycans recruit TLR-2 and -6. TLR-2, -4, and -6 are also recruited by 
oxLDL [56-60]. 
Activation of PRRs by microbial pathogens leads to an inflammatory 
response, cytokine production, leukocyte activation, fever, and, in extreme 
cases systemic inflammation/infection, edema, shock and disseminated 
intravascular coagulation, events that require activation of MAPKs (ERK, JNK, 
and p38)[56-59]. 
 
1.4.2 ERK 
The extracellular signal-regulated kinases (ERKs-1 and -2; MAPKs-3 
and -1, respectively) were the first mammalian MAPKs to be identified. The 
ERKs are most familiar as insulin and mitogen-activated MAPKs recruited by 
agonists that engage the Ras proto-oncoprotein[61, 62]. 
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In many instances, the ERKs can also be activated, in a manner 
independent of Ras, by proinflammatory stimuli including cytokines of the 
tumor necrosis factor (TNF) family, by PAMPs, such as LPS and by DAMPs, 
such as oxidized low-density lipoprotein (LDL), and crystalline uric acid. 
These mechanisms of ERK activation play an important role in innate 
immunity and inflammation. 
 
1.4.3 JNK 
The c-Jun NH2-terminal kinases (JNKs – JNK-1, JNK-2 and JNK-3) 
were initially identified as a protein kinase activity purified from cycloheximide-
treated rat liver. JNKs can be activated by mitogens and are also vigorously 
activated by a variety of environmental stresses (heat shock, ionizing 
radiation, oxidants), genotoxins (topoisomerase inhibitors and alkylating 
agents), ischemic reperfusion injury, mechanical shear stress, vasoactive 
peptides, proinflammatory cytokines, PAMPs/DAMPs and translational 
inhibitors such cycloheximide and anisomycin[63-65]. JNKs are also activated 
by tunicamycin, which leads to ER stress, implicating that JNKs are important 
effectors for the ER stress response. This has a direct implication in high-fat 
diet, which triggers ER stress in vivo, and this may play a critical role in 
triggering insulin resistance and high-fat diet-induced inflammation. 
1.4.4 P38 
P38 was originally identified as a stress- and IL-1-activated kinase that 
could phosphorylate and activate MAPK-activated protein kinase-activated 
protein kinase-1 (MK2; sect. IID1). MK2 is a member of a Ser/Thr kinase 
family that, among other substrates, phosphorylates and activates the small 
heat shock protein Hsp27[66, 67]. 
There are four p38 genes, namely p38α-δ, also called MAPK-14 
(p38α), -11 (p38β), -12 (p38γ), and -13 (p38δ)[66-74], all of which are 
preferentially activated in situ by environmental stresses, inflammatory 
cytokines and PAMPs.  
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1.5 The skin 
 
The skin plays a key role in protecting the body against external insults 
including pathogens and against excessive water loss. Its other functions are 
insulation, temperature regulation, sensation, and the production of vitamin D. 
Its outer layer is the epidermis, which consists mainly of keratinocytes, but 
also contains Langerhans cells, a specialized form of DCs (dentritic cells), and 
some pigment-producing melanocytes [75, 76]. Keratinocytes express several 
types of keratins, proteins, which are expressed only in epithelia, form 
intermediate filaments through assembly into bundles and generate the 
toughness of the epidermis [77]. In the underlying dermis several types of 
immune cells can be found such as macrophages, dermal dendritic cells, T 
cells and mast cells. They are embedded in connective tissue, which is made 
up by a mixture of extracellular matrix proteins produced by fibroblasts. The 
supply of nutrients to the skin is guaranteed by blood vessels in the dermis, 
the latter also containing lymphatic vessels and nerve endings. The epidermis 
is a constantly renewing tissue. Under normal conditions, proliferation of 
keratinocytes is restricted to the basal cell layer, where stem cells and transit 
amplifying cells are located. During an apoptosis-like process of terminal 
differentiation, keratinocytes change their expression profile and properties 
whilst migrating to the outer surface of the epidermis. This process of terminal 
differentiation generates densely packed layers with dead, flat and keratin-
filled, most upper corneal layer keratinocytes called corneocytes at the 
surface, which form a protective envelope.  
Under homeostatic conditions, the skin is colonized by a certain 
number and diversity of microorganisms on its surface. The dynamic 
equilibrium between the epidermis and microorganisms is regulated amongst 
others by sebocytes, which are located in sebaceous glands within the dermis 
and produce anti-microbial lipids, as well as by the microbes themselves, 
which produce antibiotic and antifungal substances as well as bacteriolytic 
enzymes. In addition, keratinocytes express antimicrobial substances or 
peptides constitutively and upon injury or infection, e.g. by stimulation of TLRs 
through PAMPs and DAMPs [78]. In addition to their antimicrobial properties, 
13 
certain keratinocyte-derived antimicrobial peptides as well as cytokines can 
influence the immunological properties of dendritic cells and T cells, which are 
also influenced by the stimulation of their own TLRs and can activate adaptive 
immunity [75, 76]. Given this, the skin has on one hand to ensure an efficient 
defense against pathogens and immunosurveillance, and on the other hand 
minimize excessive immune responses, which can result in disease states 
such as allergy, chronic inflammation and autoimmunity. 
 
 
1.6  Acne vulgaris 
 
Acne vulgaris - an inflammatory disease of the pilosebaceous unit - is 
the most common skin disease, affecting 60-70% of individuals at some time 
during their lives. Twenty percent of patients will have severe inflammatory 
acne that results in permanent scarring of the skin, and significant 
psychosocial effects. Acne lesions develop in the pilosebaceous unit as 
subclinical microcomedones that may evolve into closed or open comedones 
and inflammatory lesions such as papules, pustules, nodules and cysts. A 
severe inflammatory variant of acne, named acne fulminans, can be 
associated with fever, arthritis, and other systemic symptoms [79]. 
 
The pathogenesis of acne vulgaris is multifactorial, and remains to be 
completely elucidated. The main underlying cause of acne is genetic 
predisposition, the condition being inherited in an autosomal dominant pattern 
with incomplete penetrance. Other factors implicated in the development or 
severity of acne include excess sebum production and its consequences, 
hormonal factors mainly androgens, proliferation and retention of follicular 
keratinocytes resulting in follicular obstruction, the presence and activity of 
Propionibacterium acnes (P. acnes hereafter), and inflammation. The exact 
triggers for inflammation, and the molecular mechanisms involved are only 
partly elucidated however to date. One key factor that contributes to the 
inflammation observed in acne is P. acnes, a component of the normal skin 
flora, that can proliferate and be found in significantly increased numbers 
within the pilosebaceous units of patients with acne. The role of P. acnes as 
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an etiological factor in acne is well established. P. acnes is thought to 
contribute to the inflammatory nature of acne by inducing monocytes to 
secrete proinflammatory cytokines including IL-6, TNF-α, IL-1β and IL-8. In 
addition, P. acnes releases lipases, proteases and hyaluronidases that are 
considered to contribute to tissue injury. A direct link between P. acnes, the 
above-mentioned cytokines, and inflammation has never been made in vivo, 
and the exact molecular mechanism by which P.acnes induces Inflammation 
is unknown.  
 
The molecular mechanism(s) by which P. acnes induces monocyte 
cytokine release is thought to involve pattern recognition receptors (PRRs) of 
the innate immune system - notably Toll-like receptors (TLR) 2 and 9. NFkB 
activation through TLR2 signalling has been shown to be necessary for the 
production of IL-6, IL-8 and IL-12 in vitro by antigen-presenting cells (APCs) 
upon P. acnes infection [80]. In addition, TLR9 has been shown to be required 
for TNF and IFN-γ production upon P. acnes infection in vitro [81]. 
Interestingly, TLR4 expression has also been shown to be increased in the 
epidermis of patients with acne lesions [82].  
 
 
1.7  Contact Hypersensitivity 
 
Allergic contact dermatitis is a common skin disease that is caused by 
type IV delayed-type hypersensitivity responses to antigens that come into 
contact with the skin[83]. Allergic contact dermatitis is a major cause of 
occupational skin disease, and it accounts for approximately 20% of all work-
related health complaints. It results in an estimated 4 million lost work days 
and has an associated cost of almost US$400 million per year in the United 
States alone[84-86]. One of the clinically most important categories of contact 
allergens is small organic molecules that are chemically reactive (chemical 
sensitizers). They bind to self proteins to generate immunogenic neo-
antigens, through a process termed haptenization. Contact allergens are 
common in cosmetics, personal care products and jewellery, as well as in the 
workplace, regardless of whether it is in an industrial, health care or office 
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setting. Examples of common allergens are inorganic chemicals, such as 
nickel, and organic chemicals, such as those found in fragrances and 
dyes[87]. 
 
There are a series of fundamental events that lead to immune 
recognition of the hapten–self-complex, the first is percutaneous penetration 
through the stratum corneum barrier, which is the water-impermeable outer 
layer of the skin. Compounds must be less than 500 daltons for efficient 
penetration[88]. This step allows the chemical sensitizer to come into contact 
with and haptenize self proteins in the skin. Haptens or haptenated self 
proteins are recognized amongst others by innate immune mechanisms in the 
skin, and this leads to the induction of several pro-inflammatory mediators, 
including interleukin-1β[89]. As a result, skin-resident dendritic cells (DCs) 
become activated. These DCs — which may have been directly haptenated or 
could have acquired haptenated proteins from their surroundings migrate to 
skin-draining lymph nodes, where they present peptides from haptenated 
proteins to activate memory and naive T cells. In the final step, hapten-
induced inflammation recruits activated effector T cells back to the initial site 
of antigen encounter in the skin. The effector T cells release pro-inflammatory 
cytokines, such as interferon-γ, and promote the killing of haptenized cells, 
resulting in the development of the classic inflammatory rash that is seen in 
patients with allergic contact dermatits[88, 90-92].  
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1.8 Aim of this PhD thesis 
 
 Several diseases involving the immune system such as chronic-
inflammatory diseases, autoimmune diseases and auto-inflammatory 
diseases are generated, exacerbated or maintained by the active secretion of 
IL-1β. 
 
 But there are several processes in which the role of IL-1β and 
inflammasome is not known.  The aim of this thesis consists in mainly three 
projects: 
 
1) To investigate the possible role of inflammasome and IL-1β in acnes 
vulgaris; 
 
2) To determine the role of inflammasome in sensitization/tolerization 
processes involved in Contact Hypersensitivity; 
 
3)  To address the mechanisms regulating inflammasome activation. Here 
we study in detail the role of MAPK in IL-1β processing and secretion. 
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Chapter 2  
 
 
Materials and Methods 
 
 
2.1 General Remarks 
 
Standard methods are briefly described in corresponding chapters. 
 
 
2.2 Materials 
 
2.2.1 Chemicals and other consumables 
 
(2R,4R)-4-Aminopyrrolidine- 
2,4-dicarboxylic acid (APDC)  Alexis, Lausen, Switzerland 
5'Aza-2'-deoxycytydine   Sigma, Buchs, Switzerland 
Acetic acid     Fluka Chemie, Buchs, Switzerland 
Acetone     Merck, Darmstadt, Germany 
Acrylamide/bisacrylamide    Rot, Karlsruhe, Germany 
Adenosine triphosphate (ATP)  Sigma, Buchs, Switzerland 
Agarose     Sigma, Buchs, Switzerland 
Alum      Alpha Caesar, Lausanne,Switzerland 
Ammonium Persulfate (APS)  Sigma, Buchs, Switzerland 
Ampicilin     Sigma, Buchs, Switzerland 
Anisomycin     Sigma, Buchs, Switzerland 
Antimycin     Sigma, Buchs, Switzerland 
Bovine Serum Albumin (BSA)  Sigma, Buchs, Switzerland 
Bromophenol Blue     Sigma, Buchs, Switzerland 
Calcium Chloride (CaCl2)   Sigma, Buchs, Switzerland 
Cell strainers 40 and 70um  BD, Allschwil, Switzerland 
Complete proteinase inhibitor  Roche, Rotkreutz, Switzerland 
Deoxynucleotide triphosphates (dNTPs) Roche, Rotkreutz, Switzerland 
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Dimethylsufoxide (DMSO)   Sigma, Buchs, Switzerland 
Ethanol     Sigma, Buchs, Switzerland 
Eosin      Sigma, Buchs, Switzerland 
Ethylenediaminetetraacetic acid (EDTA) Sigma, Buchs, Switzerland 
ERK inhibitor     Calbiochem, London, UK 
Flasks, dishes and cell culture plates BD, Allschwil, Switzerland 
G418      Sigma, Buchs, Switzerland 
Glycerol     Sigma, Buchs, Switzerland 
Glycine     Sigma, Buchs, Switzerland 
H2D-CFDA ROS Detector   Sigma, Buchs, Switzerland 
HEPES     Sigma, Buchs, Switzerland 
Hyaluronic Acid    Sigma, Buchs, Switzerland 
Hydrogen Chloride (HCl)   Sigma, Buchs, Switzerland 
Hydrogen Peroxide (H2O2)  Sigma, Buchs, Switzerland 
JNK inhibitor II    Calbiochem, London, UK 
Kanamycin     Sigma, Buchs, Switzerland 
Lipopolysaccharide (crude LPS)  Sigma, Buchs, Switzerland 
Lipopolysaccharide (ultrapure LPS) Invivogen, Toulouse, France 
Magnesium Chloride (MgCl2)  Sigma, Buchs, Switzerland 
Methanol     Sigma, Buchs, Switzerland 
Microfilter Units (0.22, 0.45 um)  Millipore, Lausanne, Switzerland 
Mitotempo     Invitrogen, Lausanne, Switzerland 
Mitotracker green    Invitrogen, Lausanne, Switzerland 
Mitotracker deep red   Invitrogen, Lausanne, Switzerland 
MitoSOX     Invitrogen, Lausanne, Switzerland 
Monossodium Uric acid Cristals (MSU) Sam’s biotech, Zurich, Switzerland 
Nigericin     Sigma, Buchs, Switzerland 
Nitrocellulose membrane (0.22um) AmershamGE, Glattbrugg,  
      Switzerland 
Nonidet P40     Sigma, Buchs, Switzerland 
P38 inhibitor     Calbiochem, London, UK 
Parafin wax     Sigma, Buchs, Switzerland 
Paraformaldehyde (PFA)   Sigma, Buchs, Switzerland 
Phostop – phosphatase inhibitor  Roche, Rotkreutz, Switzerland 
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Potassium Chloride (KCl)   Sigma, Buchs, Switzerland 
Propidium iodide (PI)   Roche, Rotkreutz, Switzerland 
Protein A sepharose AmershamGE, Glattbrugg, 
Switzerland 
Puromycin     Sigma, Buchs, Switzerland 
R837 (imiquimod)    Invivogen, Toulouse, France 
Rotenone     Sigma, Buchs, Switzerland 
Slides Superfrost    Thermo, Wohlen, Switzerland 
Silica       Alfa Cesar, Lausanne, Switzerland 
Sodium Chloride (NaCl)   Sigma, Buchs, Switzerland 
Sodium dodecyl sulfate (SDS)  Sigma, Buchs, Switzerland 
Sodium Hydroxide (NaOH)   Sigma, Buchs, Switzerland 
Tetradecanoyl-Phorbolacetate (TPA) Sigma, Buchs, Switzerland 
Tetramethylethylenediamine (TEMED) Sigma, Buchs, Switzerland 
Triton –X100     Sigma, Buchs, Switzerland 
Trisma Base(TRIS)    Sigma, Buchs, Switzerland 
Tween 20      Sigma, Buchs, Switzerland 
Ultrafiltration units – amicon  Millipore, Lausanne, Switzerland 
Whatman 3mm paper Whatman-GE, Glattbrugg, 
Switzerland 
Whatman paper for wet transfer  Biorad, Cressier, Switzerland 
X-RAY medical film    GE, Glattbrugg, Switzerland 
Yeast Extract    Sigma, Buchs, Switzerland 
Z-VAD-fmk (pan-caspase inhibitor) Alexis, Lausen, Switzerland 
Zymosan A     Invivogen, Toulouse, France 
 
 
2.2.2 Protein size Standards 
 
Prestained protein molecular weight marker  
Fermentas, Nunningen, Switzerland 
Unstained precision plus protein standard  
      Bio-rad, Cressier, Switzerland 
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2.2.3 DNA size standards 
 
pUC mix DNA marker   Fermentas, Nunningen, Switzerland 
1kb DNA ladder New England Biolabs, Frankfurt, 
Germany 
 
 
2.2.4 Cell Culture Media and supplements/additives 
 
DMEM Gibco, Lausanne, Switzerland 
Fetal Calf Serum PAA GOLD PAA, Colbe, Germany   
Glutamax Gibco, Lausanne, Switzerland 
Hanks balanced salt solution Gibco, Lausanne, Switzerland 
Keratinocytes-SFM, EGF, BPE Gibco, Lausanne, Switzerland 
OPTIMEM Gibco, Lausanne, Switzerland 
PBS Gibco, Lausanne, Switzerland 
RPMI Gibco, Lausanne, Switzerland 
Penicilyn/Streptomycin Gibco, Lausanne, Switzerland 
Pyruvate Gibco, Lausanne, Switzerland 
Trypsin Gibco, Lausanne, Switzerland 
 
 
2.2.5 Transfection reagents 
 
Interferin PolyPlus, Illkirch, France 
Lipofectamine 2000 Invitrogen, Lausanne, Switzerland 
 
 
2.2.6 KITS 
 
BCA Protein assay Pierce/Thermo, Wohlen, Switzerland 
Bradford assay  Bio-rad,  Cressier, Switzerland 
Cytotox LDH assay Promega, Dübendorf, Switzerland 
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ECL Plus wb detection kit GE, Glattbrugg, Switzerland 
ECL pico  wb detection kit Thermo, Wohlen, Switzerland 
ECL femto wb detection kit Thermo, Wohlen, Switzerland 
ELISAs 
 Human IL-1α    R&D systems, Abingdon, UK  
 Murine IL-1α    R&D systems, Abingdon, UK 
 Human IL-1β    R&D systems, Abingdon, UK 
Murine IL-1β    R&D systems, Abingdon, UK 
Human IL-6    R&D systems, Abingdon, UK 
Murine IL-6    R&D systems, Abingdon, UK 
Human IL-8    Biolegend, Luzern, Switzerland 
Human IL-10    Biolegend, Luzern, Switzerland 
Human IL-12    Biolegend, Luzern, Switzerland 
Human TNF-α   Biolegend, Luzern, Switzerland 
 
Endofree plasmid mini/midi/maxi  Quiagen, Dusseldorf, Germany 
Gel extraction kit    Quiagen, Dusseldorf, Germany 
NBT/BCIP substrate kit   Promega, Dübendorf, Switzerland 
Plasmid mini/midi/maxi    Quiagen, Dusseldorf, Germany 
 
 
2.2.7 Primary antibodies 
 
 14-3-3θ 9638 cell signalling 
14-3-3θ sc-59414 santa cruz 
b-actin 2020 cell signalling 
b-tubulin 2128 cell signalling 
ASC alx-210-905 alexis 
BAD 9292 cell signalling 
BAX 2772 cell signalling 
BAX sc-20067 santa cruz 
BCL-XL 2764 cell signalling 
BCL-XL sc-7195 santa cruz 
beclin-1 3495 cell signalling 
BIM 2933 cell signalling 
caspase-1 sc-622 santa cruz 
cleaved caspase-3 9664 cell signalling 
COXiv 4850 cell signalling 
cytocrome C 4280 cell signalling 
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human mature 17 kDa IL-1β  D116 cell signaling 
human total  IL-1β  D37 cell signaling 
mouse IL-1β  ilbm R&D systems 
NLRP3 ag-20b-0014 adipogen 
P38α 2371 cell signalling 
P38β 2339 cell signalling 
P38γ 2307 cell signalling 
P38δ 2308 cell signalling 
  phospho BAD ser112 9291 cell signalling 
phospho BAD ser136 4366 cell signalling 
phospho BAD ser155 9297 cell signalling 
phospho BAX ser184 ab111391 abcam 
phospho BCLXL ser62 ab30655 abcam 
phospho BIM ser69 4585 cell signalling 
phosphoJNK 9251 cell signalling 
phosphoserine ab9332 abcam 
  JNK 9252 cell signalling 
JNK sc-7345 santa cruz 
Thioredoxin ab86255 abcam 
Txnip k0204-3 MBL 
VDAC 4661 cell signalling 
   
 
   
2.2.8 Secondary antibodies 
 
Appropriate HRP-conjugated secondary antibodies were used from New 
England Biolabs and proteins were detected using ECL reagent, pico and 
femto substrates (thermo scientific). 
 
 
2.2.9 siRNAs and shRNAs 
 
siRNAs and shRNAs were bought from Sigma, Buchs, Switzerland 
 
 
2.2.10 Plasmids 
 
All plasmids were bought from addGENE 
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2.2.11 Bacterial strains 
E.coli BL21    AmershamGE, Glattbrugg, Switzerland  
OneShot TOP10   Invitrogen, Lausanne, Switzerland 
 
 
2.2.12  Eukaryotic cell lines 
 
COS-1    ATCC, Manassas, US 
HEK 293-T    ATCC, Manassas, US 
J774.1    ATCC, Manassas, US 
THP-1     ECACC, London, UK 
 
 
2.2.13  Standard buffers and solutions 
 
PBS    
  NaCl  140 mM  
  KCl  30 mM  
  Na2HPO4 6.5 mM 
  KH2PO4 1.5 mM 
  pH adjusted to 7.4 
 
TBST 
  NaCl  0.15 M 
  Tween 20 0.05% 
  TRIS/HCl 10 mM  (pH 8.0) 
 
Co-IP buffer 
  NaCl  10mM 
  EDTA  15 mM 
  Triton-X100 0.1% 
  TRIS/HCl  50 mM  (pH 7.5) 
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Abstract 
 
 
 
Acne vulgaris is a potentially severe skin disease associated with 
colonization of the pilosebaceous unit by the commensal bacteria 
Propionibacterium acnes (P. acnes) and inflammation. P. acnes is 
considered to contribute to inflammation in acne, but the pathways 
involved are unclear. Here we reveal a previously unknown mechanism 
that regulates inflammation in acne. We show that interleukin-1β (IL-1β) 
mRNA and the active processed form of IL-1β are abundant in human 
inflammatory acne lesions, and identify P. acnes as a trigger of 
monocyte-macrophage NLRP3-inflammasome activation, IL-
1β processing and secretion. In mice, cutaneous neutrophilic 
inflammation induced by P. acnes is critically dependent on IL-1β and 
the NLRP3-inflammasome of myeloid cells, but independent of toll-like 
receptor 2 (TLR2). These findings show that the commensal P. acnes - 
by activating the inflammasome - can trigger an innate immune 
response in the skin that contributes to inflammatory acne, thus 
establishing the NLRP3-inflammasome and IL-1β as critical therapeutic 
targets in acne. 
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Acne vulgaris is a chronic inflammatory disease of the pilo-sebaceous 
unit. It is the most common skin disease, affecting approximately 80% 
of individuals at some time during their lives1. The disease is multifactorial, 
and four processes are considered to play a pivotal role in the formation of 
acne lesions, namely: increased sebum production; altered follicular 
keratinization; inflammation; and bacterial colonization of the pilo-sebaceous 
unit by Propionibacterium acnes (P. acnes). Androgen-induced increased 
sebum production and follicular hyperkeratinisation/plugging are thought to be 
initial steps leading to a change of the pilo-sebaceous milieu that favors 
proliferation of P. acnes2. Pro-inflammatory cytokines including interleukin-1α 
(IL-1α) and tumour necrosis factor α (TNF-α) are, amongst others, considered 
to date to be responsible for the further follicular hyperkeratinization and the 
inflammatory lesions characteristic of acne2-4. Controversy exists however 
concerning the significance of the commensal P. acnes in the development of 
acne2. It has been suggested that P. acnes may contribute to the 
development of inflammatory lesions by releasing chemotactic substances, 
and by acting on TLR2 to stimulate the secretion of IL-6 and IL-8 by follicular 
keratinocytes, and IL-1β, TNF-α, IL-8 and IL-12 by monocytic cells2,5-7. Direct 
evidence of relevant triggers of inflammation in acne in vivo, and the precise 
molecular mechanisms involved, remain however largely unknown. 
Innate immunity is our first line of defense against pathogens 
(pathogen-associated molecular patterns, PAMPs) and danger (danger-
associated molecular patterns, DAMPs). Responses to PAMPs and DAMPs 
are mediated by germ-line encoded pattern recognition receptors (PRRs). 
Among the PRRs, certain Nod-like receptor (NLRs) family members including 
NLRP1, NLRP3, NLRC4 and AIM2, have the ability to mediate responses to 
PAMPs and DAMPs and subsequently assemble to form high-molecular 
weight, caspase-1-activating molecular platforms called inflammasomes, that 
control the activation and secretion of the proinflammatory cytokines IL-1β 
and IL-188,9. Based on the observations that deregulation of the 
inflammasome and IL-1β has been linked to a rare genetic autoinflammatory 
syndrome associating pyogenic arthritis, pyoderma gangrenosum and acne, 
named PAPA syndrome10, and furthermore, that acne is characterized by 
neutrophilic infiltration of the skin, a distinctive feature observed in transgenic 
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mice carrying a mutation in the NLRP3 gene equivalent to the human 
mutation associated with Muckle-Wells Syndrome11, we considered that the 
inflammasome and IL-1β may be directly involved in the pathogenesis of 
acne. 
 In this work, we show that the proinflammatory cytokine IL-1β is 
abundant in its active form in human acne lesions, and that the production of 
IL-1β by P. acnes-exposed cells of monocytic lineage requires activation of 
the NLRP3-inflammasome. We also demonstrate in mice, that P. acnes 
reproduces neutrophilic skin lesions histologically resembling acne pustules in 
a NLRP3-inflammasome dependent manner. Moreover, we show that IL-1β 
plays a crucial in situ role for P. acnes-induced neutrophil infiltration of the 
skin, thus implicating IL-1β as a novel potential therapeutic target in acne. 
 
RESULTS 
P. acnes induces IL-1β secretion in monocytic cells 
First, we assessed in situ IL-1β production in human acne lesions by 
immuno-histochemistry. The active, processed form of IL-1β was at the site of 
cutaneous inflammation, notably together with monocytes, histiocytes 
surrounding the pilosebaceous unit (Fig. 1a and Supplementary Fig. 1). 
Accordingly, we detected elevated levels (>50 mean fold increase) of IL-1β 
mRNA (Fig. 1b) selectively in skin biopsies of papulo-pustular acne. To test 
whether P. acnes is a pro-inflammatory trigger for IL-1β production observed 
in acne lesions, human monocytes were exposed to live or heat-inactivated P. 
acnes in vitro. Within 24 hours of exposure to P. acnes, significant pro-IL-1β 
synthesis and subsequent mature-IL-1β secretion could be detected by 
western blotting in cell lysates and cell culture supernatants, respectively (Fig. 
1c). Moreover, exposure of monocytes to live or heat-inactivated P.acnes led 
to the secretion of IL-1β, IL-6, TNF-α and IL-8 in a multiplicity of infection 
(MOI)-dependent manner (Fig. 1d-g). Interestingly, monocytes secrete 
nanograms of IL-1β within 24h of P. acnes exposure (Fig. 1d), without the 
requirement for pre-stimulation with ultra-pure LPS (upLPS), suggesting that 
P. acnes triggering of IL-1β production is biologically relevant since picograms 
of IL-1β are known to be already active in vivo12. 
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Figure 1 P. acnes induces cytokine secretion by myeloid cells. (a) Human sections of papulo-pustular 
acne lesions (n=10) or normal skin samples (n=10) from distinct individuals stained with anti-mature-IL-
1β antibody or isotype control. Bottom left panel, high magnification of selected area from the top panel. 
Scale bar = 100mm. (b) IL-1β mRNA levels in acne lesions (AV, n=12) and normal skin (NS, n=6) 
measured by qPCR. The relative IL-1β mRNA abundance against ribosomal protein L27 (RPL27) 
mRNA levels were analyzed and normalized with the average of normal skin. **P≤0.005 by Mann–
Whitney two-tailed test for acne lesions compared to normal skin. (c) Freshly isolated human monocytes 
were exposed to live or heat-inactivated (HI) P. acnes at multiplicity of infection =100 (MOI). Western 
blot analysis of pro- and mature-IL-1β p17 in cell lysates and supernatants, respectively. (d-h) Human 
monocytes were stimulated with indicated MOI of live or HI P. acnes for 24h. IL-1β (d), IL-6 (f), TNF-α 
(g) and IL-8 (h) release from P. acnes-exposed monocytes was determined by ELISA. (h) ELISA of IL1-
β secreted from upLPS (100ng ml-1)-primed human monocytes exposed to P. acnes. (i) Primary human 
keratinocytes were exposed to P. acnes or irradiated with UVB (0.26 mW/cm2, 6 min). After 24h, IL-1β 
secretion was measured by ELISA. ****P ≤ 0.00001 and ***P ≤ 0.0001 by one-way analysis of variance 
(ANOVA) with Bonferroni post-test compared to unstimulated cells (medium). Results are presented as 
mean and s.d and are representative of experiments performed three times. 
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(PMA) resulted in stronger IL-1β secretion upon P. acnes exposure (Fig. 1h 
and Supplementary Fig. 2). Although keratinocytes are able to sense certain 
DAMPs such as UV and subsequently drive IL-1β-dependent innate immune 
responses in the skin13-15, they were unable to secrete mature IL-1β when 
exposed to P. acnes alone or in the presence of monocyte-conditioned 
medium (Fig. 1i and Supplementary Fig. 3). Keratinocytes were also unable 
to secrete IL-6 and TNF-α upon P. acnes exposure, but did secrete low levels 
of IL-8 when exposed to very high MOI of live P. acnes (Supplementary Fig. 
4).  
Taken together, the above experiments suggest that cells of myeloid 
origin are primarily involved in the detection of P. acnes that leads to the 
mature IL-1β production occurring in inflammatory acne lesions of the skin. 
 
P. acnes induces IL-1b secretion in a NLRP3-inflammasome-dependent 
manner 
Enzymatic processing of the inactive precursor of IL-1β (pro-IL-1β) by 
caspase-1 and subsequent secretion of mature IL-1β are essential steps 
required for its function. Caspase-1 is initially expressed as an inactive 
pre???????? ?????? ???? ??? ?????????? ??? ???? ????????????? ?? ????????????
multiprotein complex composed of a NLRP family member, ASC and 
caspase-116. In P. acnes-exposed human monocytes, the secretion of IL-1β 
could be inhibited in the presence of the caspase inhibitor Z-VAD (Fig. 2a). 
Moreover and in spite of normal pro-IL-1β levels (Supplementary Fig. 5c), 
THP1 cells transfected with caspase-1-shRNA (Fig. 2b and Supplementary 
Fig. 5a) and bone marrow-derived (BMDC) from caspase-1 deficient mice 
(Casp1-/-) (Fig. 2e) were unable to secrete IL-1β either upon P. acnes 
exposure or stimulation with the inflammasome activators monosodiumurate 
crystals (MSU) or nigericin (Supplementary Fig. 5d). In contrast, monocyte 
production of IL-6, TNF-α and IL-8 was not inhibited by Z-VAD, demonstrating 
that the secretion of these cytokines upon P. acnes exposure is independent 
of inflammasome activation and IL-1β signaling (Supplementary Fig. 6). 
Furthermore, THP1 cells transduced with ASC-shRNA (Fig. 2c and 
Supplementary Fig. 5a) or NLRP3-shRNA (Fig. 2d and Supplementary Fig. 
5a)  
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Figure 2 P. acnes activates caspase-1- and the NLRP3-inflammasome. (a) Human monocytes were 
primed with upLPS and exposed to medium, live P. acnes (MOI=100) or MSU (150mg ml-1) in the 
presence of vehicle (DMSO) or pan-caspase inhibitor (Z-VAD-fmk, 10mM) for 24h. Supernatants were 
tested for IL-1β secretion by ELISA and for mature-IL-1β release (IL-1b p17) by western blot. (b-d) 
ELISA of secreted IL-1b from PMA (500 nM) -differentiated THP-1 cells transfected with shRNA to 
Caspase-1 (shCASP1) (b), ASC (shASC) (c), NLRP1 (shNLRP1) or NLRP3 (shNLRP3) (d) and 
exposed to live P. acnes (MOI=100). Lamin A/C shRNA (shLamin A/C) was used as irrelevant control. 
(e-g) ELISA of secreted IL-1β from WT, Caspase-1-/- (Casp1-/-) (e), Asc-/- (f), Nlrp3-/- (g), murine bone-
marrow-derived dendritic cells (BMDC) pulsed with upLPS and exposed to medium, P. acnes 
(MOI=300) or MSU crystals in the presence of vehicle (DMSO) or Z-VAD-fmk where indicated. (h) 
NLRP1 and NLRP3 mRNA levels in human acne lesions (AV, n=12) and normal skin (NS, n=6) 
measured by qPCR. The relative NLRP1 and NLRP3 mRNA abundance against RPL27 mRNA levels 
were analyzed and normalized with the average of normal skin. *P≤0.05 by Mann–Whitney two-tailed 
test for acne lesions compared to normal skin. (i) Scatter-plot showing the correlation (Spearman's rank 
correlation) between the NLRP3 and IL-1β mRNA expression in human acne biopsies.  (a-g) * P ≤ 0.05, 
**P ≤ 0.001 and ***P ≤ 0.0001 by one-way analysis of variance (ANOVA) with Bonferroni post-test. 
Mean and s.d are presented. Results are representative of experiments repeated three times. 
Z-VAD         -    +      -   +      -   + 
a 
IL-1 p17 
b c d 
h 
e f g 
  
0
5
10
15
20
25
hI
L-
1 
 (n
g 
m
l-1
)
**
**
0
200
400
600
800
shLamin A/C DMSO
shLamin A/C Z-VAD
shCASP1 DMSO
hI
L-
1 
 (p
g 
m
l-1
) **
**
0
1
2
3
4
5
shLamin A/C
shASC
hI
L-
1 
 (n
g 
m
l-1
) **
0.0
0.2
0.4
0.6
0.8
1.0
shLamin A/C
shNLRP1
shNLRP3
hI
L-
1 
 (n
g 
m
l-1
) *ns
0.0
0.5
1.0
1.5
 WT  DMSO
WT  Z-VAD
Casp1-/-  DMSO
m
IL
-1
 
(n
g 
m
l-1
)
***
***
***
***
0.0
0.5
1.0
1.5
WT
Asc-/-
m
IL
-1
 
(n
g 
m
l-1
)
***
***
0.0
0.5
1.0
WT
Nlrp3-/-
m
IL
-1
 
(n
g 
m
l-1
)
**
***
SN 
i 
AV NS AV NS 
0.01
0.1
1
10
100
1000 ns
fo
ld
 o
f c
ha
ng
e
*
NLRP1 NLRP3
0.1 1 10 100 1000
1
10
100
1000
10000
NLRP3 fold of change
IL
-1
 
fo
ld
 o
f c
ha
ng
e r=0.9
p=0.0004
38 
also exhibited reduced IL-1β secretion upon P. acnes exposure, while pro-IL-
1β synthesis was not affected (Supplementary Fig. 5e). To further 
demonstrate the role of the inflammasome in P. acnes induced IL-1β - 
secretion, we also exposed BMDC from mice deficient for ASC (Asc-/-) or 
NLRP3 (Nlrp3-/-) to P. acnes. Indeed, Asc-/- and Nlrp3-/- BMDC exhibited 
strongly reduced IL-1β secretion when compared to wild type (WT) cells (Fig. 
2f, g).  
Distinct bacterial components may be recognized by different 
inflammasomes. Indeed, it has been shown that NLRP3 and NLRC4 (Ipaf)17 
are also able to sense certain bacterial components. In contrast to the 
NLRP3-inflammasome, the NLRC4-inflammasome does not appear to be 
involved in P. acnes-induced IL-1β production by BMDC (Supplementary 
Fig. 7a). Furthermore, using shRNA-transduced THP1 cells (Supplementary 
Fig. 5b), we observed that NLRP1 is also dispensable for IL-1β secretion 
upon P. acnes exposure (Fig. 2d). Interestingly, and in concordance with the 
above observations, expression analysis in human acne biopsies revealed 
increased levels of NLRP3 mRNA as compared to normal skin, whereas the 
mRNA expression levels of NLRP1 and NLRC4 was not altered (Fig. 2h and 
Supplementary Fig. 7b). Importantly, in acne skin biopsies the levels of 
NLRP3 mRNA correlated significantly with the levels of IL-1β mRNA (Fig. 2i). 
These data demonstrate that P. acnes is a potent activator of the 
NLRP3-inflammasome in cells of monocytic lineage.  
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P. acnes-induced NLRP3-inflammasome activation depends on bacteria 
uptake, lysosomal maturation, ROS and potassium efflux 
Current models of NLRP3-inflammasome activation include the 
generation of reactive oxygen species (ROS)18-20, potassium efflux18, and 
lysosomal damage with release and activation of cathepsin B for stimuli 
requiring phagocytosis such as MSU and silica20,21. Exposure of THP1 cells to 
cytochalasin D (Cyt. D), an inhibitor of actin filament assembly, abrogated the 
uptake of P. acnes (Fig. 3a). Likewise, IL-1β maturation and secretion in 
upLPS-stimulated monocytes exposed to P. acnes or MSU was reduced by 
Cyt. D, whereas the response to the non-crystalline NLRP3-inflammasome 
activator nigericin was not affected (Fig. 3b). Interestingly, both pro-IL-1β 
synthesis and IL-1β release from non upLPS-stimulated monocytes exposed 
to P. acnes were impaired by Cyt. D (Fig. 3c). These observations 
demonstrate that internalization of the bacteria by antigen presenting cells 
(APCs) is essential for both pro-IL-1β synthesis (signal-1) and its cleavage 
into the active, secreted form of IL-1β (signal-2). Furthermore, specific 
blockade of the lysosomal cysteine protease cathepsin B, but not cathepsin D 
resulted in decreased IL-1β secretion by P. acnes- or silica-exposed 
monocytes (Fig. 3d), showing that lysosomal rupture is also required for IL-1β 
secretion in response to P. acnes. In contrast, none of the cathepsin inhibitors 
affected IL-1β release upon exposure to exogenous ATP. 
To analyze further mechanism(s) possibly leading to NLRP3-
inflammasome activation upon P. acnes exposure, we pre-treated human 
monocytes with upLPS to induce generation of pro-IL-1β and subsequently 
exposed them to P. acnes in the presence of ROS inhibitors, namely 
diphenyleneiodonium (DPI) or ammonium pyrrolidinecarbodithioate (PDTC). 
Under these conditions, IL-1β secretion by monocytes exposed to P. acnes or 
MSU was reduced by the ROS inhibitors (Fig. 3e). It has been previously 
shown that triggering of ROS in human granulocytes is caused by potassium 
efflux22. Inhibiting K+ efflux, either by increased extracellular potassium 
concentration or by blockade of potassium channels with glibenclamide23 also 
resulted in a significant reduction of IL-1β release by P. acnes- or MSU-
exposed monocytes (Fig. 3f) whereas TNF-α secretion was unaffected (Fig. 
3g).  
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Figure 3 Inflammasome activation by P. acnes requires ROS production, K+ efflux, phagocytosis 
lysosomal destabilization. (a) THP1 cells treated with vehicle (DMSO, blue line) or cytochalasin D (Cyt. 
D, 2.5mM, green line) were exposed to CFSE-labeled live P. acnes (MOI=100) for 4h or left untreated 
(control, red line). Bacteria uptake was analyzed by FACS. (b) IL-1b secretion from human monocytes 
primed with upLPS and incubated with vehicle (DMSO) or Cyt.D 1h prior to exposure to medium, live P. 
acnes, MSU or nigericin (20mM). (c) Non-upLPS-primed human monocytes were exposed for 6h to P. 
acnes in the absence (DMSO) or presence of Cyt. D or Z-VAD-fmk. ELISA of secreted IL-1β 
(supernatant) and western blot of pro- and mature-IL-1β p17 (cell lysates) are presented. (d, e) IL-1β 
secretion from human monocytes primed with upLPS and incubated with cathepsin B- (Cath.B, 10mM) 
or cathepsin D-inhibitor (Cath.D, 10mM) (d) or ROS inhibitors (DPI, 10mM; PDTC, 10mM) (e). (f, g) IL-
1β and TNF-α release from upLPS-primed human monocytes treated with the potassium channel 
blockers (Glibenclamide, 100mM; KCl, 65mM) 1h prior to exposure to medium, P. acnes or MSU were 
determined after 6h by ELISA. (h) Secreted IL-1b from WT or P2x7-/- murine BMDC primed with upLPS 
and exposed for 24h to medium or P. acnes (MOI=300) was measured by ELISA. (b-h) **P ≤ 0.001 and 
***P ≤ 0.0001 by one-way analysis of variance (ANOVA) with Bonferroni post-test. Presented means 
and s.d. are representative of at least three independent experiments.  
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We also assessed whether cellular ATP plays a role in P. acnes-
induced IL-1β production. BMDC from ATP receptor P2x7-/- mice released 
similar amounts of IL-1β as BMDC from WT mice when exposed to P. acnes 
or MSU while failing to respond to ATP (Fig. 3h). This suggests that P. acnes 
did not induce ATP release from exposed monocytic cells. 
Taken together, these data demonstrate that inflammasome activation 
and the secretion of mature IL-1β by monocytes upon exposure to P. acnes 
requires phagocytosis, lysosomal damage with release and activation of 
cathepsin B, generation of ROS, and potassium efflux. 
 
P. acnes induces NLRP3-inflammasome-dependent IL-1β production 
and cutaneous neutrophilic inflammation in vivo  
To assess whether the NLRP3-inflammasome is involved in sensing P. 
acnes in vivo, and if IL-1β plays a role in P. acnes-associated cutaneous 
inflammation, we injected P. acnes intradermally in the ear of WT mice. Such 
intradermal injection of P. acnes resulted in significant ear swelling within 24 
hours (Fig. 4a), production of pro- and mature-IL-1β (Fig. 4b), and a strong 
inflammatory response histologically comprised primarily of neutrophils (Fig. 
4c). When inflammasome-deficient Asc-/- mice were compared to WT mice 
after intradermal injection of P. acnes, ear swelling (Fig. 4a), production of 
pro- and mature-IL-1β (Fig. 4b), as well as inflammation (Fig. 4c) were all 
reduced. In Nlrp3-/- mice, the magnitude of ear swelling and production of IL-
1β were also reduced, similarly to Asc-/- mice (Fig. 4a, b). These observations 
are consistent with our in vitro data, and indicate that NLRP3-inflammasome-
dependent IL-1β triggers neutrophilic inflammatory lesions at the site of P. 
acnes infection. To further verify this hypothesis, P. acnes-injected mice were 
treated intraperitoneally with an IL-1 receptor antagonist (IL-1Ra), a 
monoclonal anti-IL-1β antibody, or a TNF-α inhibitor (Etanercept) prior to 
intradermal administration of P. acnes. A significant reduction in ear swelling 
and neutrophilic inflammation were observed in IL-1Ra- and anti-IL-1β-treated 
mice as compared to TNF-α inhibitor-treated mice (Fig. 4c, d), thus 
confirming the crucial and selective role of IL-1β in the generation of 
cutaneous neutrophilic inflammation in response to P. acnes in vivo. In 
accordance with these findings, Il-1rI-/- mice also exhibited significantly 
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reduced ear swelling after P. acnes injection (Fig. 4e). 
 
 
 
Figure 4 P. acnes induces NLRP3-inflammasome-dependent cutaneous inflammation in vivo. (a) WT 
(n=13), Asc-/- (n=13) and Nlrp3-/- (n=7) mice were injected intradermally with P. acnes (20x106 CFU in 
20ml PBS, left ear) or with an equal volume of PBS (right ear). Ear swelling as measured 24h later is 
presented. The ear thickness before injection was considered as 100% and served as a reference. (b) 
Pro- and mature-IL-1β western blot of ear protein extracts from WT, Asc-/- and Nlrp3-/- mice challenged 
with P. acnes. (c) Histology of WT mice injected with P. acnes, PBS or P. acnes with anti-IL-1β. 
Histology of an Asc-/- mouse challenged with P. acnes is also shown. Scale bar = 500 mm. Upper right 
panel, high magnification of selected area from the left panel. Scale bar = 50mm. (d) Ear swelling in WT 
mice treated with vehicle (n=11), three intraperitoneal injections of IL-1Ra (Anakinra, 150mg kg-1, n=13) 
at 8h intervals, a single i.p. injection of anti-IL-1β antibody (1mg kg-1, n=12), or Etanercept (5mg kg-1, 
n=12) 1h prior to P. acnes or PBS challenge. (e) Ear swelling in WT (n=7) and Il-1rI -/- mice (n=7) 
injected intradermally with P. acnes or with PBS as above. (a, d, e) *** P≤0.0001 by two tailed unpaired 
Student’s t test for WT P. acnes challenged mice compared to mice deficient for the indicated genes or 
subjected to the indicated treatments. 
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To determine which cell types are required for triggering IL-1β-
dependent inflammation upon P. acnes infection in vivo, we generated bone 
marrow chimeras consisting of WT mice reconstituted with either WT, Asc-/- or 
Nlrp3-/- bone marrow. Resulting chimeras were injected intradermally with P. 
acnes as above. Ear swelling (Fig. 5a) and cutaneous inflammatory infiltrates 
(Fig. 5b) were reduced in chimeric mice harboring Asc-/- or Nlrp3-/- myeloid 
cells when compared to mice transplanted with WT bone marrow. Moreover, 
the in vivo response to P. acnes was restored when Asc-/- or Nlrp3-/- mice 
were reconstituted with WT bone marrow (Fig. 5c). These data indicate that 
the cutaneous inflammatory response to P. acnes in vivo is mediated by cells 
of myeloid lineage. It also excludes a significant possible role of Langerhans 
cells, known to be radio-resistant, in the P. acnes induced in vivo 
inflammatory response.  
 
 
Figure 5 Cells of myeloid origin mediate immune responses to P. acnes in vivo. (a, b) WT mice 
reconstituted with WT (n=12), Asc-/- (n=11) or Nlrp3-/- (n=8) bone marrow were challenged with P. acnes 
or PBS as described above. The resulting swelling (a) and histology of the injected ear (b) are 
presented. Scale bar = 500 mm. (c) Ear swelling in WT (n=6), Asc-/- (n=6) or Nlrp3-/- (n=6) reconstituted 
with WT bone marrow and challenged P. acnes or PBS as above. (a) *** P≤0.0001 by two tailed 
unpaired Student’s t test for WT reconstituted with WT bone marrow and challenged with P. acnes 
compared to mice reconstituted with bone marrow deficient for the indicated genes. 
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Taken together, our data demonstrate that IL-1β secreted from myeloid 
cells in a NLRP3-inflammasome-dependent manner, is responsible for the 
induction of a cutaneous neutrophilic inflammatory response to P. acnes in 
vivo. 
 
 
Cutaneous inflammation induced by P. acnes in vivo is independent of 
TLR2 
The pathogen recognition receptor TLR2 can trigger innate immune 
responses upon recognition of a broad range of PAMPs, including gram-
positive bacterial factors such as peptidoglycan, lipoteichoic acid, and 
macrophage-activating lipopeptides24. It has been shown that TLR2-signaling 
is involved in triggering the production of proinflammatory cytokines in 
response to P. acnes in vitro25. We therefore assessed whether TLR2 
signaling is required for the cutaneous inflammation triggered by 
subcutaneous P. acnes in vivo. After having verified that bacterial uptake was 
not affected by TLR2-deficiency (Supplementary Fig. 8), we injected P. 
acnes intradermally to Tlr2-/- mice and compared swelling and inflammatory 
infiltration of the injected ear to that of WT mice. In contrast to what would be 
predicted from previously reported in vitro data25, no significant difference in 
ear swelling or cutaneous inflammation was observed between Tlr2-/- and WT 
mice (Fig. 6a). Production of pro-IL-1β as detected by western blotting of 
injected ears (Fig. 6b), did not require TLR2, as pro-IL-1β levels were similar 
in the ears of Tlr2-/- and WT mice. Furthermore, treatment of Tlr2-/- mice with 
IL1-Ra or anti-IL-β antibody significantly reduced ear swelling (Fig. 6a) and 
cutaneous inflammation (Fig. 6c), thus clearly indicating that TLR2 is 
dispensable for the in vivo cutaneous inflammatory response to P. acnes. 
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Figure 6 P. acnes-induced cutaneous inflammation in vivo is independent of TLR2. (a-c) WT (n=10) and 
Tlr2-/- mice (n=10) were injected intradermally with P. acnes or PBS 1h after IL-1Ra treatment (n=9) or 
anti-IL-1β antibody (n=9), where indicated. Ear swelling (a) and histology (c) are presented. Scale bar = 
500 mm. *** P≤0.0001 by two tailed unpaired Student’s t test for WT P. acnes challenged mice 
compared to Tlr2-/- mice for each given treatment. (b) Western blot analysis of pro- and mature-IL-1β in 
ear protein extracts from WT and Tlr2-/- mice. 
 
 
 
DISCUSSION 
Here, we show that the common anaerobic gram positive commensal 
of normal skin P. acnes, can modulate skin immune responses triggered by 
innate immune receptors. Indeed, sensing of P. acnes by myeloid cells in the 
skin and subsequent activation of the NLRP3-inflammasome appears to be a 
critical event in the formation of inflammatory skin lesions. Mature IL-1β 
released by myeloid cells upon sensing of P. acnes by the NLRP3-
inflammasome likely plays a central role in driving neutrophil-rich inflammation 
in acne, as indicated by the high levels of IL-1β observed in human acne 
lesions, in mouse neutrophilic cutaneous lesions induced by P. acnes, and the 
dependence of this on the NLRP3-inflammasome. Thus we show here that 
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two of the four pivotal processes considered to be involved in acne lesion 
development - namely follicular colonization by P. acnes and inflammation - 
are linked at a molecular level, and the NLRP3-inflammasome provides this 
molecular link by sensing P. acnes and triggering IL-1β production in myeloid 
cells surrounding the pilosebaceous unit.  
  To date, the exact molecular mechanisms by which DAMPs and 
PAMPs lead to NLRP3-inflammasome oligomerization and activation are not 
fully understood. Several models have been proposed including ROS-
generation, K+ efflux and lysosomal rupture26,27. Here we provide evidence 
here that all three mechanisms are involved in P. acnes-mediated activation 
of the NLRP3-inflammasome. Noteworthy, we show that bacterial 
internalization due to phagocytosis by cells of myeloid origin is essential for 
both pro-IL-1β synthesis (signal-1) and inflammasome-dependent cleavage 
into its active secreted form (signal-2). It was previously unclear if and 
precisely how the commensal bacteria P. acnes can trigger an inflammatory 
response in the skin. Our experiments reveal that NLRP3-deficiency in 
myeloid cells is sufficient to prevent P. acnes-induced inflammation in vivo, 
and that P. acnes selectively induces inflammasome activation in myeloid 
cells but not keratinocytes in vitro. This suggests that triggering inflammation 
by P. acnes is dependent on location, and more specifically upon adequate 
access of the bacterium to myeloid cells as well as their ability to phagocytose 
the bacteria and trigger a NLRP3-inflammasome-dependent innate immune 
response. Previous studies histologically assessing early events in skin 
biopsies from acne patients have revealed that macrophages are present in 
high numbers in the immediate proximity of the pilosebaceous follicle of 
uninvolved acne skin as well as in early stage inflammatory lesions28,29. 
Moreover, it has been shown in skin biopsies of inflammatory acne lesions 
that perifollicular macrophages contain phagocytosed P. acnes30. These 
macrophages are likely to serve as sentinels in acne by triggering a NLRP3-
inflammasome dependent inflammatory response when they gain access to 
P. acnes released into the perifollicular environment following the onset of 
follicular rupture provoked by follicular obstruction and intrafollicular P. acnes 
overgrowth. 
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Based on in vitro studies showing that macrophage TLR2 mediates P. 
acnes-induced cytokine production in vitro, it has been postulated that TLR2 
could be an appropriate therapeutic target in acne25. Indeed, Kim et al. 
reported that the production of IL-6 by mouse peritoneal macrophages, as 
well as the secretion of IL-8 and IL-12 by human monocytes exposed to P. 
acnes occurs in a TLR2-dependent manner in vitro25. Although the above 
cytokines, notably IL-8 are known to play a role in neutrophilic inflammation, 
we found that P. acnes-induced cutaneous inflammation is TLR2-independent 
in vivo. Moreover, the production of IL-1β  at the site of P. acnes-induced 
cutaneous inflammation in TLR2-deficient mice was comparable to wild-type 
control mice, and blockade of IL-1R and IL-1b both inhibited P. acnes-induced 
inflammation in TLR2-deficient mice. It therefore appears that, although TLR2 
can sense P. acnes and trigger inflammatory cytokine responses in vitro, it 
may not be a critical component required for driving inflammation in response 
to P. acnes in the skin in vivo.  
The therapy of inflammatory acne can be challenging. Lack of 
response, side effects, or recurrences following systemic therapy using 
antibiotics or retinoids are quite frequent31. Alternative effective therapies for 
acne are thus needed. Recently, clinical reports suggesting a therapeutic 
effect of drugs targeting IL-1β signaling in patients suffering from 
autoinflammatory syndromes in which acne is a symptom have appeared32-34. 
Furthermore, and in accordance with our data, recent interim results from a 
phase 2 double blind placebo controlled trial assessing the effect of a 
monoclonal antibody to IL-1β (Gevokizumab, Xoma-052) have shown that 
Gevokizumab given for three consecutive months induced significant 
improvement of inflammatory acne 
(http://www.clinicaltrials.gov/ct2/show/NCT01498874?term=Gevokizumab&ra
nk=1, http://investors.xoma.com/releasedetail.cfm?ReleaseID=731711). 
Taken together, we show here that P. acnes, one of the factors 
considered to contribute to acne, is a potent trigger of NLRP3-inflammasome 
assembly and IL-1β production in myeloid cells in vitro and in vivo. Moreover, 
we provide the first functional in vivo evidence that activation of the NLRP3-
inflammasome by the anaerobic microbe P. acnes is a critical event in the 
formation of inflammatory acne lesions, and that this mechanism of 
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inflammation in acne can be selectively prevented by targeting inflammasome 
components or IL-1β. Our data thus indicates novel avenues for targeted 
treatment of the most debilitating features of acne, namely painful 
inflammatory skin lesions and subsequent scarring. 
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Supplementary figure 1 CD68 positive cells infiltrate acne lesions. Human sections of acne 
lesions (papulo-pustules, left panel) or normal skin (right panel) samples stained with anti-CD68 
antibody. Scale bar = 100m.  
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Supplementary figure 2 P. acnes induces IL-1 secretion in human and murine cells. Human 
THP1 cells untreated (a) or differentiated with PMA (500nM) (b) were exposed to indicated MOI 
of P. acnes. Murine BMDC untreated (c) or primed with upLPS (100ng ml-1) (d) were stimulated 
with P. acnes (MOI=300). IL-1 release was determined by ELISA. Means and s.d. from one 
representative experiment of three are presented.  
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Supplementary figure 3 P. acnes does not induce IL-1 secretion in human primary 
keratinocytes. Human kerationocytes (KC) were cultured in monocyte P. acnes-conditioned 
medium (50%) and further exposed to indicated MOI of live P.acnes (black bars). IL-1 release 
was determined by ELISA. Secretion of IL-1 by infected monocytes (white bar) served as a 
control. Means and s.d. from one representative experiment repeated twice.  
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Supplementary figure 4 Cytokine secretion from human keratinocytes exposed to P. acnes. 
Primary human keratinocytes were exposed to P. acnes or to UVB (0.26 mW/cm2, 6 min). After 
24h, IL-6 (a), TNF (b) and IL-8 (c) secretion were measured by ELISA. ***P ≤  0.0001  by  one-
way analysis of variance (ANOVA) with Bonferroni post-test compared to medium exposed cells. 
Results are presented as mean and s.d and are representative of experiments performed twice. 
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Supplementary figure 5 THP1 cells stably expressing ASC, Caspase-1 or NLRP3 gene-specific 
shRNA show impaired IL-1 processing. (a, b) THP1 cells were infected with lentivirus carrying 
gene-specific shRNA as indicated. The efficacy of ASC, Caspase-1 and NLRP3 knock-down was 
determined by western blot (a) and the efficacy of NLRP1 knock-down was estimated by real-
time PCR (b). *** P≤0.0001  by   two   tailed  unpaired  Student’s   t test for THP1 NLRP1 shRNA 
compared to THP1 Lamin A/C shRNA. (c, e) Pro-IL-1 synthesis by THP1 cells expressing 
indicated shRNA upon PMA (500nM) treatment (c) or P. acnes infection (MOI=100) (e) was 
determined by western blot. Actin served as loading control. (d) The functional efficiency of each 
knockdown was determined by stimulation of PMA–differentiated, shRNA-transduced THP1 
cells with MSU (150g ml-1) and nigericin (20M). IL-1 release was measured by ELISA. 
***P ≤  0.0001  by  one-way analysis of variance (ANOVA) with Bonferroni post-test. 
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Supplementary figure 6 P. acnes infected monocytes secrete IL-6, TNF and IL-8in a caspase-
1-independent manner. Freshly isolated human monocytes were stimulated with indicated MOI 
of P. acnes in the presence of vehicle (DMSO) or pan-caspase inhibitor (Z-VAD-fmk, 10M) for 
24h. Release of IL-1 (a), IL-6 (b), TNF (c) and IL-8 (d) were determined by ELISA. *P ≤  0.05  
and ***P ≤  0.0001  by  one-way analysis of variance (ANOVA) with Bonferroni post-test. Means 
and s.d. from one representative experiment of two are presented. 
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Supplementary figure 7 NLRC4 inflammasome is not activated by P. acnes. (a) ELISA of 
secreted IL-1 from Nlrc4-/- murine bone-marrow-derived dendritic cells (BMDC) pulsed with 
upLPS and exposed to P. acnes (MOI=300). (b) NLRC4 mRNA levels in human acne lesions 
(AV, n=12) and normal skin (NS, n=6) measured by qPCR. The relative NLRC4 mRNA 
abundance against RPL27 mRNA levels were analyzed and normalized to the average of normal 
skin. Results are representative of experiments performed twice. 
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Supplementary figure 8 P. acnes phagocytosis is independent of TLR2. BMDC from WT (blue 
line) or Tlr2-/- (green line) mice were infected with CFSE-labeled P. acnes (MOI=300) for 18h or 
left untreated (red line). Bacteria uptake was analyzed by FACS. Data are representative of one 
experiment repeated twice. 
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METHODS 
Mice. Asc-/- C57BL/6 mice35 were obtained from Genentech (San Francisco). 
Nlrp3-/- C57BL/6 mice36 were obtained from Prof. Jürg Tschopp (Biochemistry 
Institute, University of Lausanne, Epalinges, Switzerland). Caspase1-/- 
C57BL/637 and Nlrc4-/- C57BL/6 mice38 were kindly provided by by Wolf-
Dietrich Hardt (Institute of Microbiology, ETH Zürich, Switzerland). P2x7-/- 
C57BL/639, Il-1rI-/- C57BL/640 were obtained from Jackson Laboratories (Bar 
Harbor). Tlr2-/- C57BL/6 mice 41 were kindly provided by Marc Donath 
(Department of Biomedicine, University Hospital Basel, Switzerland). Wild-
type C57BL/6 mice were obtained from the breeding facility of the University 
of Zürich. All the experiments were approved by the local Animal Protection 
Authorities. 
 
Human skin sampling. All human skin biopsies were collected upon 
approval of Local Ethical Committees and were conducted according to the 
Declaration of Helsinki Principals. 
 
Bacteria. Propionibacterium acnes (DSM 1897, DMSZ, Braunschweig, 
Germany) was cultured in anaerobic conditions on cooked meat medium 
(Difco, Becton Dickinson) supplemented with yeast extract (5mg ml-1, Sigma-
Aldrich), K2HPO2 (5mg ml-1, Fluka), resaurin (1mg ml-1, Sigma-Aldrich), and 
cystein chloride (0.5mg ml-1, Sigma-Aldrich) at 37°C. Bacteria were harvested 
by centrifugation at 5,000 at 10 min, washed and suspended in PBS or 
medium for experiments. P. acnes cultures were hear-inactivated by 
incubation at 95°C for 10 min. 
 
Cells. Human THP1 promonocytic leukemia cells were grown in RPMI 1640 
medium (Invitrogen), supplemented with 10% FCS (Invitrogen), 1% Antibiotic-
Antimycotic (Invitrogen), 1 mM sodium-pyruvate (Invitrogen), 2 mM GlutaMAX 
solution (Invitrogen).  
Monocytes from healthy donors (10 different donors) were obtained from 
peripheral blood mononuclear cells (PBMC). PBMC were purified from buffy-
coats (obtained from Blood Donation Center in Schlieren, Switzerland) using a 
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density gradient (Ficoll-Paque, Pharmacia). Monocytes were sorted from 
PBMC using anti-CD14-labeled magnetic beads (MACS, Miltenyi Biotech, 
Germany) according to the manufacturer’s instructions. 
Mouse bone-marrow-derived dendritic cells (BMDC) were obtained by 
differentiation of bone marrow cells, from 6-10 weeks old mice, for 8 days in 
RPMI 1640 medium supplemented like above and in the presence of 20% X-
63 cells (mGM-CSF-producing cells) supernatant.  
Human primary keratinocytes have been cultivated as previously described42. 
Cells were irradiated with UVB (Medisun HF-54, Schulze & Böhm or UV802L, 
Waldmann; 0.26 mW/cm2 for 6 min) in keratinocyte–serum-free medium 
(Invitrogen) or exposed to live P. acnes. In co-culture experiments human 
primary keratinocytes were stimulated with indicated MOI of live P. acnes in 
the presence of monocyte P.acnes-conditioned medium. Briefly, primary 
monocytes were stimulated with live P. acnes (MOI=30), conditioned medium 
was harvested after 24 and applied to the keratinocytes in the absence or 
presence of live P. acnes. 
For infection experiments, THP1 cell were differentiated for 3h with 500 nM 
phorbol-12-myristate-13-acetate (PMA, Sigma-Aldrich), washed and platted 
one day before stimulation, human monocytes and mouse BMDC were 
primed overnight with ultra-pure LPS (E. coli 0111:B4, 100ng ml-1, InvivoGen) 
in antibiotic-free medium. Twelve hours later, medium was replaced and cells 
were infected with live or heat-inactivated P. acnes at the indicated multiplicity 
of infection (MOI) or stimulated with monosodiumurate crystals (MSU, 150mg 
ml-1), nigericin (20mM, Enzo Life Sciences), silica (500mg ml-1, gift of Pr. J. 
Tschopp), Zymosan A (200mg ml-1, Sigma-Aldrich) for indicated time. ATP 
(5mM, Sigma-Aldrich) that was added to the cells 30 min prior to collection of 
supernatants. All experiments for western blotting analysis were performed in 
OptiMEM serum-free medium (Invitrogen). 
The following chemical inhibitors were used: Z-VAD-fmk (Z-VAD, 10mM, Enzo 
Life Sciences), NADPH-oxidase inhibitor dibenziodolium chloride (DPI, 10mM, 
Sigma-Aldrich); NO-synthase inhibitor ammonium pyrrolidinecarbodithioate 
(PDTC, 10mM, Sigma-Aldrich), Glybenclamide (100 mM, Sigma-Aldrich), KCl 
(65 mM, Fluka), cathepsin B inhibitor (CA-074Me, 10mM, Calbiochem) or 
cathepsin D inhibitor (Pepstatin A, 10mM, Sigma-Aldrich), cytochalasin D 
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(2.5mM, Fluka). Inhibitors were added 1h before cell stimulation where 
applicable. 
 
Generation of THP1 cells stably expressing shRNA. THP1 cells stably 
expressing shRNA against lamin A/C, ASC, caspase-1, NLRP1 and NLRP3 
were obtained by transducing THP1 cells with lentiviral particles. Briefly gene 
specific shRNA were generated by inserting oligonucleotides targeting lamin 
A/C, ASC, caspase-1, NLRP318 or NLRP113 into pSUPER vector 
(Oligoengine) and subsequent cloning into lentiviral vector pAB286.1 as 
described elsewhere18. Second-generation packaging plasmids pMD2-VSVG 
and pCMV-R8.91 (gift of Pr. J. Tschopp) were used for lentivirus production 
and infection.  
 
Western blotting. Cell culture supernatants were precipitated by addition of 
0.25 volumes of trichloroacetic acid (100% w/v, Sigma-Aldrich), 10 min 
incubation on ice and centrifugation for 5 min at 14,000g. Protein pellet was 
washed twice with ice-cold acetone (Sigma-Aldrich), centrifuged as above and 
dried at 70°C. Cells were lysed with buffer (10mM Tris pH 7.5, 1% NP-40, 
150mM NaCl, 5mM EDTA,) containing and protease inhibitor cocktail 
(Roche). Proteins were separated on a NuPAGE gel (Invitrogen) in 
accordance with the manufacturer’s protocol and transferred to a Hybond-C-
Extra membrane (Amersham Biosciences) by electroblotting. The membranes 
were blocked with 5% gelatin (Top Block, Juro) in 1× PBS and 0.5% Tween-
20 and then probed with primary antibodies as follows: rabbit polyclonal anti-
human mature (17 kDa) IL-1β (D116, Cell Signaling), rabbit polyclonal anti-
human IL-1β (Cell Signaling), goat polyclonal anti-mouse IL-1β (R&D 
Systems), rabbit polyclonal anti-ASC (AL117, Enzo Life Sciences), rabbit 
polyclonal anti-human caspase-1 (sc622, Santa Cruz), mouse IgG2b anti-
NLRP3 (Cryo-2, Enzo Life Sciences), rabbit polyclonal anti-b-actin (Cell 
Signaling). 
Appropriate HRP-conjugated secondary antibodies were used and proteins 
were detected using ECL reagent (GE Healthcare). 
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RNA isolation and real-time PCR. RNA were isolated from THP1 cells using 
the Qiagen RNeasy kit (Qiagen) following manufacturer's instructions, and 
total RNA was converted into cDNA by standard reverse transcription with 
Superscript III reverse transcriptase (Invitrogen). Quantitative PCR was 
performed using Power SYBR Green PCR Master Mix (Applied Biosystems). 
The primer sequences were obtained from 
http://pga.mgh.harvard.edu/primerbank/:  
for human RPL27: forward 5′-ATCGCCAAGAGATCAAAGATAA -3′, reverse 
5′-TCTGAAGACATCCTTATTGACG-3’.  
for human NLRP1: forward 5′- ATTCCAGTTTGTGCGAATCCA-3′, reverse 5′-
GTTCCTTGGGGAGTATTTCCAG-3. 
for human IL-1b: forward 5′-CACGATGCACCTGTACGATCA -3′, reverse 5′-
GTTGCTCCATATCCTGTCCCT-3’.   
for human NLRP3: forward 5′-TCTCATGGATTGGTGAACAGC -3′, reverse 5′-
GGTCCCCCAGAGAATTGTCA-3’.  
for human NLRC4: forward 5′- AGGTCCCACAACTCGTCAAGCT -3′, reverse 
5′- TGCTCACACGATTTCCCGCCAA-3’.  
The real-time PCR included an initial denaturation at 95°C for 10 min, 
followed by 40 cycle of 95°C for 30 s, 55°C for 1 min, 72°C for 1 min, and one 
cycle of 95°C for 1 min, 55°C for 30 s, 95°C for 30 s. 
ELISA. Cell culture supernatants were collected at indicated time point and 
analyzed for presence of cytokines by ELISA. Secreted human and mouse IL-
1β and IL-6 were determined by ELISA kits from R&D Systems. Human and 
mouse TNF-α and IL-8 ELISA kits were purchased from Biolegend. All ELISA 
assays were performed according to the manufacturer’s instructions. 
 
Mouse intradermal infection model. P. acnes (DMSZ 1897) was 
intradermally injected (20x106 in 20ml of PBS) into left ears of mice. Right 
ears were injected with an equal volume of PBS. IL-1Ra treated mice: 
C57BL/6 mice received three intraperitoneal (i.p.) injections of IL-1 receptor 
antagonist (IL-1Ra, Anakinra, Kineret 150mg kg-1, Amgen) or PBS at 8h 
intervals. One hour after first i.p. injection of IL-1Ra mice received intradermal 
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injections of P. acnes or PBS. TNF-α inhibitor (Etanercept, 5mg kg-1, Wyeth 
Europa Ltd) or anti-IL-1β antibody (200 mg per mouse, kindly provided by 
Novartis, Basel, Switzerland) were injected  i.p. 24h before  intradermal 
injection of P. acnes or PBS. Bone marrow chimera: indicated mice were 
lethally irradiated (10 Gy) and subsequently transplanted with indicated bone 
marrow. After hematopoietic reconstitution (8 weeks later) mice were 
intradermally injected with P. acnes or PBS.The ear thickness was measured 
using a micro caliper (Mitutoyo, Japan) before and 24h after bacterial 
injection. The percentage of ear thickness was calculated by comparing the 
ear thickness before (100%) and 24h after injection. 
 
Immunohistochemistry. Human acne skin samples or mouse ear samples 
were cross-sectioned and stained with H&E and with rabbit anti-human 
mature IL-1b (Abcam, ab53175) antibody, isotype control antibody (Abcam, 
ab27478), or mouse-anti human CD68 (DAKO, M0876) antibody where 
indicated. 
 
P. acnes internalization assays. Bacteria were washed three times with 
PBS and then labeled with CFSE (1mM, Invitrogen) for 20 min at 37°C and 
extensively washed with medium. THP1 cells or BMDC were infected with 
indicated MOI of live P. acnes for 6h or 24h respectively then cells were 
extensively washed an analyzed by flow cytometry (FacsCanto A, BD). Where 
indicated, Cytochalasin D (2.5mM) was added to cells 1h before bacteria. 
 
Statistical analysis. The statistical analysis for qPCR performed on human 
samples was performed using Mann–Whitney test. Data obtained from in vitro 
experiments were subjected to by one-way analysis of variance (ANOVA) with 
Bonferroni post-test. Data obtained from in vivo studies were subjected to 
unpaired Student’s t test. Differences were considered significant when: * 
P≤0.05, ** P≤0.001, *** P≤0.0001 and **** P≤0.00001. Spearman's rank 
correlation analysis was used to investigate the possible correlations between 
NALP3 and IL-1β mRNA expression levels. All statistics were performed using 
GraphPad Prism software. 
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Abstract 
 
 
 
 
Efficient priming of adaptive immunity depends on danger signals 
provided by innate immune pathways. As an example, inflammasome-
mediated activation of caspase-1 and IL-1β is crucial for the 
development of reactive T cells targeting sensitizers like 
dinitrofluorobenzene (DNFB). Surprisingly, DNFB and 
dinitrothiocyanobenzene provide cross-reactive Ags yet drive opposing, 
sensitizing vs tolerizing, T cell responses. In this study, we show that, in 
mice, inflammasome-signaling levels can be modulated to turn 
dinitrothiocyanobenzene into a sensitizer and DNFB into a tolerizer, and 
that it correlates with the IL-6 and IL-12 secretion levels, affecting Th1, 
Th17, and regulatory T cell development. Hence, our data provide the 
first evidence that the inflammasome can define the type of adaptive 
immune response elicited by an Ag, and hint at new strategies to 
modulate T cell responses in vivo.  
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The prime goal of the immune system is to protect us from harm by 
pathogens. To fulfill this function, it relies on sequential activation of innate 
and adaptive immune systems. The latter is characterized by the generation 
of very large repertoire of cells, each one with a specific target that 
proliferates rapidly when encountering the right Ag, adapting efficiently to the 
host environment. However, it requires clues from the less specific but faster 
innate immune response (1). Previously regarded as a primitive mechanism 
for cleaning up pathogen debris, it is now recognized as a remarkably specific 
system that is essential for priming adaptive immunity. Pattern recognition 
receptors are key sensors of the innate immune system, which are capable of 
recognizing molecules that are unlikely to vary much, due to their essential 
function for the pathogen survival. Both the transmembrane receptors called 
TLRs and intracellular receptors called NOD-like receptors (NLR) belong to 
this family (2, 3). 
Although very efficient and elaborate, this dual immune surveillance is 
prone to making errors, such as exaggerated responses to environmental 
substances leading to severe skin (contact hyper-sensitivity (CHS)) or lung 
(asthma) diseases. Environmental chemicals may be categorized in respect to 
their potency as sensitizers: whereas weak sensitizers will induce a feeble 
adaptive immune response in a selected number of people, potent sensitizers 
will induce strong CHS in 100% of humans. Although several reports have 
shown that local irritation is important for the development of CHS (4 –7), the 
underlying molecular mechanisms are still largely unknown. Because 
Freund’s adjuvant is used to boost the adaptive immune response during 
vaccination and has recently been demonstrated to activate both NLRs and 
TLRs (8), we postulated that CHS also depends on danger signaling through 
similar receptors. 
Others and we have recently demonstrated that CHS, due to small 
irritant chemicals such as dinitrofluorobenzene (DNFB), is dependent on the 
inflammasome (9, 10). This protein complex is composed of three proteins: 1) 
an NLR of the NALP family (NALP, neuronal apoptosis inhibitory protein, 
CIITA, HET-E, TP1 (NACHT) LRR- and pyrin domain); 2) the adaptor protein 
apoptosis speckled-like protein with a caspase recruitment domain (ASC); 
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and 3) caspase-1 (3). This complex regulates the activity of caspase-1 and, 
consequently, of the proinflammatory cytokines IL-1β and IL-18. We found 
that mice lacking NALP3, ASC or the IL-1 receptor, failed to develop CHS 
after exposure to certain contact sensitizers, suggesting that the 
inflammasome plays a key role in the priming of adaptive immunity. 
DNFB belongs to a family of structurally related chemical compounds 
with high sensitizing properties that have been used as model haptens to 
study effector T cell development in vivo. Dinitrochlorobenzene (DNCB) and 
trinitrochlorobenzene (TNCB) belong to the same family and, like DNFB, 
induce a strong CHS response. Dinitrothiocyanobenzene (DNTB), by contrast, 
fails to induce a strong immune response in vivo, despite its high structural 
homology to DNFB. Interestingly, several reports suggest that DNTB may 
induce immunological tolerance to itself and to cross-reactive dinitrophenyl 
compounds, in particular to DNFB (11–14). We hypothesized that the potency 
of a contact sensitizer may be linked to its capacity to provide danger signals 
mediated by the inflammasome, rather than its antigenicity, and that the 
inflammasome is implicated in tolerance versus sensitization mechanisms. 
We therefore studied the effect of DNTB and DNFB on inflammasome 
signaling in vitro, as well as the effect of inflammasome modulation on 
sensitization and tolerance in vivo. 
 
 
Results 
 
DNFB and DNTB provide similar epitopes yet differ in their capacity to 
activate the inflammasome and induce contact hypersensitivity 
DNFB, DNCB, TNCB, and DNTB have been used as model haptens to 
study contact hypersensitivity and T cell reactivity in mice (11–14). As we had 
previously observed that TNCB activates the inflammasome in vitro and in 
vivo, we decided to study the effect of DNCB, DNFB, and DNTB on this 
signaling pathway. We found that primary keratinocytes exposed to DNFB, 
DNCB, and TNCB, but not DNTB, secrete significant amounts of active IL-1β, 
in a dose dependent manner, while the viability of the cells was not affected at 
these concentrations (Fig. 1A). This effect was inhibited by the caspase-1 
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inhibitor zYVAD, strongly suggesting an inflammasome dependent 
mechanism. Interestingly, the active component of poison ivy, urushiol, also 
potently activates IL-1β secretion, as previously reported (15). Because 
detergents with irritant properties potentiate allergic responses (4–6) and have 
been reported to promote IL-1β secretion by keratinoctes (15), we included 
SDS in our assays and found that it could also trigger IL-1β activation. Our 
results hinted that DNTB might fail to trigger danger signals necessary to 
induce CHS in vivo. Indeed, DNFB, DNCB, and TNCB induce strong 
sensitization (Fig. 1B), while DNTB is a weak sensitizer at best (11–14). The 
difference in the sensitizing potency of these molecules may be due to the 
antigenicity of these molecules, but our results rather suggest that it is linked 
to their capacity to provide danger signals through the activation of the 
inflammasome. 
 
 
 
Figure 1. DNFB and DNTB provide similar epitopes, yet differ in their capacity to activate the 
inflammasome and induce contact hypersensitivity. A, Primary keratinocytes exposed in vitro to contact 
sensitizers such as TNCB (10 µg/ml), DNCB (10 µg/ml), DNFB (0.5–10 µg/ml), and urushiol (5 µg/ml) 
secrete IL-1β, whereas DNTB (0.5–10 µg/ml), which induces tolerance, does not. The skin-irritant SDS 
(15 µg/ml) also induced significant IL-1β release, but not benzalkonium (BZK). IL-1β activation is 
blocked by the specific caspase-1 inhibitor zYVAD. B, Mice sensitized at day 0 and 1 on the left ear, 
then challenged at day 5 on the right ear develop contact hypersensitivity to TNCB, DNCB, and DNFB 
but not to DNTB, as shown by the ear swelling 24 h after challenge. Interestingly, mice sensitized to 
DNFB and challenged with DNTB develop CHS, whereas DNTB-sensitized mice challenged with DNFB 
do not. Taken together, these findings suggest that both molecules provide cross-reactive epitope(s), 
but that only DNFB provides danger signals necessary to mount a CHS. (Cells: n = 4 independent 
duplicates, mice = 5–6/group). 
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We found that DNFB-sensitized mice display a strong reaction to 
DNTB (Fig. 1B). Our data are consistent with previously published 
observations and tend to confirm that DNFB and DNTB provide epitopes that 
can be recognized by the same T cells, yet differ in their capacity to prime the 
adaptive immunity (11, 12, 16). Although the value of DNTB as a tolerogen is 
still debated (17, 18), this suggests that the level of inflammasome signaling 
induced by a given molecule may better predict its sensitizing potential than 
the antigenic properties itself. 
 
Danger signaling mediated by the inflammasome allows sensitization to 
DNTB, while blocking danger signaling prevents DNFB sensitization 
IL-1β had been previously reported to play a key role for the CHS 
response to small irritants like DNFB, acting as an adjuvant promoting effector 
T cell response (19). We reasoned that whether the inflammasome is 
responsible for the activation of IL-1β, it should be possible to turn weak 
sensitizers into strong sensitizer by providing danger signals. Mice exposed 
twice on the right ear to DNTB failed to mount an immune response when 
challenged with DNFB on the contralateral ear (Fig. 2A), although a direct 
irritant effect of DNFB could be readily observed. However, when SDS was 
applied topically during DNTB sensitization, DNFB elicited a strong immune 
reaction (Fig. 2A). Danger signaling by these two adjuvants failed to trigger 
CHS in the absence of hapten co-presentation (AOO), ruling out a nonspecific 
effect on T cell development during the challenge phase. It did not either 
further enhance the response to DNFB, which can activate the inflammasome 
very efficiently on its own (Fig. 2A). These data are in accord with previous 
reports showing an adjuvant effect of a similar detergent (sodium lauryl 
sulfate) in men (4, 5). Moreover, concomitant injection of IL-1β, but not PBS 
alone, favored the development of CHS to DNTB (Fig. 2A). Conversely, the 
sensitizing effect of DNFB was abrogated when inflammasome signaling was 
inhibited, either by the local application of a caspase-1- inhibitor (zYVAD), as 
previously reported (20, 21). Likewise, the sensitizing capacity of DNFB was 
abrogated by the systemic injection of an IL-1 receptor antagonist (Anakinra) 
(Fig. 2B), which is consistent with a report showing local intradermal injection 
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of IL-1ra 6–24 h before sensitization (22). These results are concordant with 
the response of mice deficient for ASC and IL-1R. 
 
 
 
 
Figure 2. Concomitant danger signaling allows sensitization to DNTB, while blocking danger signaling 
prevents DNFB sensitization. A, DNTB- sensitized mice (days 0 and 1 on the left ear) challenged with 
DNFB (day 5 on the right ear) do not develop CHS, except if danger signals, such as i.v. IL-1β or topical 
SDS, are provided at the time of sensitization. Application of either SDS or IL-1β alone, in the absence 
of any hapten (AOO), had no effect, while neither could further increase the sensitization capacity of 
DNFB. B, Blocking of danger signals provided by DNFB during sensitization, using i.v. IL-1Ra 
(Anakinra) or topical zYVAD prevents the development of CHS. Similar results are obtained when the 
sensitization is performed in ASC or IL-1R-deficient mice. C, SDS increases the sensitizing capacity of 
DNTB in ASC-/- but not ASC-/- littermates. (n=5 mice/group, unless indicated in the figure). The irritant 
effect DNFB alone is limited, as observed in mice treated with AOO during the sensitization phase later 
challenged with a single application of DNFB (A and C). 
 
Although our in vitro data strongly suggested that SDS induces IL-1β 
activation through an inflammasome-mediated process, we had no proof that 
it was the case for its in vivo adjuvant effect. We therefore assessed the effect 
of SDS in ASC-deficient mice. SDS potently and significantly increased the 
sensitizing capacity of DNTB in ASC heterozygote mice but only very weekly 
in their littermate ASC-deficient mice (Fig. 2C). Hence, the adjuvant effect we 
observed for SDS is mediated primarily by the inflammasome. Taken 
together, these data strongly suggest that the inflammasome is a key 
mediator of danger signals that prime the adaptive immune response directed 
against potent contact sensitizers. 
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Exposure to topical sensitizers in the absence of inflammasome-mediated 
danger signals leads to tolerance 
The tolerogenic effect of DNTB is a matter of debate. Indeed, some 
find it to behave as a weak sensitizer (17, 18), whereas others find it induces 
tolerance (11, 13, 14). There is, on the contrary, no doubt on the fact that 
DNFB is a strong sensitizer. In our experimental setting, DNTB not only failed 
to elicit CHS, but also induced tolerance, as mice painted on two consecutive 
days on their shaved belly could not be sensitized any longer with DNFB, 
whereas the response to Oxazolone was normal (Fig. 3A). As DNTB and 
DNFB provide cross-reactive epitopes, which are different from those 
provided by oxazolone (16), our findings suggest that the mechanism 
implicated in the diminished response to DNFB is tolerance, as previously 
detailed (11–14) and not a more general non- specific immunosuppression. 
 
 
Figure 3 Exposure to topical sensitizers in the absence of inflammasome-mediated danger signals 
leads to tolerance. A, Exposure of BALB/c mice to DNTB 5 days before sensitization and challenge with 
DNFB results in tolerance to DNFB, as indicated by the decrease in ear swelling. Pretreatment with 
DNTB does not however impair the response to another contact sensitizer like oxazolone, suggesting 
strongly that the effect of DNTB on DNFB response is hapten specific. The irritant effect DNFB and 
oxazolone alone are limited, as observed in mice treated with AOO during the sensitization phase later 
challenged with a single application of either DNFB or oxazolone (A). B, Induction of tolerance is a 
cellular mediated process as adoptive transfer of cells of the spleen and lymph nodes of DNTB, but not 
DNFB, treated BALB/c mice blocks the development of CHS to DNFB in the recipient mice. In IL-1R 
deficient mice, DNFB fails to induce CHS. Adoptive transfer of cells derived from DNFB-treated mice 
block development of CHS to DNFB in wild-type BALB/c mice, strongly suggesting that in the absence 
IL-1β signaling, DNFB induces tolerance. C, Induction of tolerance to DNFB by DNTB is also observed 
in C57BL/6 mice. Adoptive transfer of cells from DNFB treated ASC-deficient mice, but not WT C57BL/6 
mice, blocks CHS to DNFB in naive wild-type recipient mice, suggesting that DNFB induces tolerance in 
mice that cannot activate the inflammasome. (n= 5 mice/group). 
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Because we found that, in the absence of danger signaling, DNFB is 
no longer a potent sensitizer, we decided to test its capacity to induce 
tolerance in this setting. As ASC and IL-1R-deficient mice fail to mount a 
proper CHS to DNFB, we could not study tolerance directly in these strains (9, 
10, 23, 24). However, we could expose ASC and IL-1R-deficient mice to 
DNFB and then transfer lymphoid cells in a wild-type recipient mouse, where 
sensitization and tolerance can be studied. Indeed, several groups have 
observed that DNTB-induced tolerance to DNFB can be transferred to a 
recipient syngeneic mouse, using adoptive transfer of lymph nodes and 
spleen cells (11, 14). We first confirmed these findings, showing that naive 
mice injected with lymph node and spleen extracted cells from DNTB-, but not 
DNFB-, treated mice failed to mount a CHS response when later sensitized 
and challenged with DNFB (Fig. 3B). The extent of tolerance induction was 
similar in mice directly pretreated with DNTB (Fig. 3A). Likewise, mice injected 
with cells from DNFB-primed IL-1R- or ASC- deficient mice showed a 
significant decrease in their capacity to mount an immune response to DNFB 
(Fig. 3, B and C, respec- tively), suggesting that tolerance develops in the 
absence of inflammasome-mediated IL-1β activation. Hence, we could 
demonstrate that the balance between sensitization and tolerance depends 
on danger signaling levels mediated by IL-1β rather than the antigenic 
properties of the hapten used. 
 
 
Cytokine profile in tolerance vs sensitization in mouse lymph nodes 
These results strongly suggested that the inflammasome determines, 
either at the skin or draining lymph node level, whether suppressive or 
effector T cells are produced. We reasoned that the cytokine environment 
surrounding T cells specific for the DNTB/ DNFB epitope may vary 
accordingly. We therefore determined the cytokine profile in draining lymph 
nodes of DNFB treated ears from ASC deficient mice and their control 
littermates. Mice sensitized with DNFB on day 1 and 2 were sacrificed at day 
3 and the draining lymph nodes were dissociated and cultivated for 5 days. 
Under these conditions, we could not detect significant amounts of secreted 
IL-1β (data not shown). It is important to note here that IL-1β is secreted in 
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minute amounts and that IL-6, one of its bona- fide downstream target, is 
significantly increased after the injection of femto-moles of IL-1β, hence 
making IL-6 a surrogate marker for active IL1β secretion (25). Interestingly, 
we found that wild- type lymph nodes secreted significantly higher amounts of 
IL-6 and IL-12/23 than those from ASC-deficient mice, suggesting a cytokine 
environment likely to favor a Th1 and Th17 response and hamper regulatory T 
cell (Treg) development (26, 27) (Fig. 4 and see below). These results are 
consistent with a previous report showing that IL-12 can turn DNTB into a 
strong sensitizer (14). IL-10 secretion, which antagonizes LC migration and 
IL-12 priming of T cells (28), was slightly higher in ASC deficient mice, but the 
difference was not statistically significant and the very low levels observed 
may undermine the relevance of our finding. Hence, our results suggest but 
do not prove that the inflammasome may modulate the secretion levels of IL-
10, which may in turn regulate T cell fate. 
 
 
Figure 4. Cytokine profile in tolerant vs sensitized mouse lymph nodes. Lymph node cells from DNFB 
treated ASC-/- mice (days -5 and -4 before lymph nodes extraction) secrete significant amounts of IL-6 
and IL-12, as determined by ELISA. In contrast, cells from their ASC-/- littermates secreted only small 
amounts of these cytokines. IL-10 levels were slightly increased in ASC-/- cells, yet statistical 
significance was not reached. (n =4 mice/group). ND: Non-detectable. 
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Mechanisms of tolerance transfer 
 
The mechanism of DNTB induced tolerance is still controversial. 
However, early experiments, including adoptive transfer studies, have 
suggested that regulatory T cells (previously called suppressive T cells) may 
be implicated (11, 12, 14). We therefore studied the impact of regulatory cells 
on tolerance to DNFB. We first analyzed the repartition of CD4+ CD25+ 
FoxP3+ T cells in lymph nodes draining the skin of DNFB treated ASC-
deficient mice and their control littermates. We found that the overall number 
of CD4+ CD25+ FoxP3+ cells was the same, suggesting either that Tregs are 
not implicated in tolerance or that the DNFB-specific Treg population variation 
is too small to affect the total number of regulatory T cells present in the 
lymph node (Fig. 5A), as previously reported (14). We reasoned that if Tregs 
do play a role in tolerance induction, adoptive transfer of Treg depleted T cells 
would not protect recipient mice from DNFB. We therefore extracted lymph 
node and spleen cells from DNTB-exposed donor mice and used magnetic 
bead-associated cell sorting to remove CD4+CD25+ double positive cells. We 
found that after adoptive transfer of these cells, sensitivity to DNFB was 
partially restored (Fig. 5B). We cannot fully rule out that this type of depletion 
could have a less specific general effect on Tregs numbers, affecting general 
repressor cytokine level, but this is unlikely because the over- all number of 
Treg is not affected by ASC deficiency (Fig. 5A). Interestingly, when DNFB-
treated animals were used as donors, depletion of Treg did not induce further 
increase in the response to DNFB, suggesting that there are no or very few 
DNFB-specific Treg cells in naive mice (Fig. 5B). Taken together with 
previous reports (11, 12, 14), our results suggest that molecules which are 
present on the skin but do not activate the inflammasome are nevertheless 
presented to T cells, resulting the development of a small population of Tregs 
with suppressive capacity. This is consistent with the current belief that, in 
non-inflammatory conditions, LC travel to the lymph nodes (although at low 
level) and are tolerigenic (29). Moreover, this is also consistent with the 
observation 
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that the vast majority of people exposed to nickel, a weak hapten that does 
not activate the inflammasome (H. Watanabe, manuscript in preparation), 
exhibit nickel-specific Tregs with suppressive activity, but nickel-allergic 
patients do not (30). Hence, the Treg pathways may represent a default 
pathway, which is negatively regulated by danger signals, including the IL-1β 
activation mediated by the inflammasome. 
 
 
 
 
 
 
Figure 5. Mechanisms of tolerance transfer and inflammasome dependency. A, The repartition of CD4+ 
CD25+ FoxP3+ Tregs is the same in lymph node cells extracted from DNFB treated ASC heterozygote 
and deficient mice, as demonstrated by FACS staining. B, Adoptive transfer of DNTB exposed donor 
mice fails to induce tolerance to DNFB in the recipient mouse, if CD4+ CD25+ cells are removed by 
magnetic associated cell sorting, before their transfer. (n=4 mice/group). 
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Discussion 
 
The central role of innate immunity in the activation of the adaptive 
immune response is no longer a matter of debate, in particular regarding TLR 
signaling. We herein provide evidence that danger signaling through the 
inflammasome can also affect the fate of the adaptive immune response. 
Others and we had already shown that efficient sensitization does not occur in 
the absence of the inflammasome and IL-1β (9, 10, 22), yet these studies did 
not evaluate the impact of this signaling pathway, or its absence, on the type 
of adaptive response elicited. We now provide evidence that the 
inflammasome may act as a major switch between tolerance and 
sensitization, laying emphasis on the sequential role of innate immunity and 
adaptive immunity in CHS (Fig. 6). Indeed, we found that DNTB fails to 
activate the inflammasome in vitro, unlike other members of this family. 
Furthermore, DNTB becomes a sensitizer if concomitant inflammasome 
signaling is provided. More importantly, blocking inflammasome signaling 
turns a bona fide sensitizer, DNFB, into a tolerizer. Taken together, these 
findings suggest that the inflammasome controls the development of tolerance 
or sensitization to (irritant) chemicals. Hence, NLR and TLR not only share 
structural resemblance, but also a similar function. Because both signaling 
pathways ultimately result in NF-kB activation, it is reasonable to think that a 
certain amount of redundancy is present. We therefore propose that 
stimulation of TLR, IL-1R, IL-18R, and IL-12R may all favor the development 
of CHS to DNTB or other Ags, as reported for IL-12 (14). Consequently, NLR 
activation may be an interesting target as an adjuvant for vaccines and tumor 
vaccination, and it should be noted here that DNCB has been used to 
promote inflammation and favor immune-rejection in metastatic melanoma 
patients (31). 
Our data further suggest that the Treg-mediated development of tolerance 
may represent a default pathway in noninflammatory conditions, as we 
observed that ASC deficiency favors tolerance to haptens present in the skin. 
The potential physiologic benefit to this may be to avoid unnecessary/harmful 
T cell responses against Ags that are not accompanied by significant cell 
stress or damage, and therefore are unlikely to originate from a pathogen 
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(introducing the notion of an environmental self). This hypothesis may have 
important implications in the fields of virology and oncology. As an example, 
human papillomaviruses elicit little response from the immune system, 
although they can provide highly antigenic epitopes (32). Danger signaling 
mediated by imiquimod-induced TLR7-triggering results in a rapid destruction 
of the lesions by T cells (33), suggesting that the virus “invisibility” depends on 
the absence of inflammation. Cancer development and immune-escape may 
rely on similar mechanisms, as most tumors develop without eliciting 
inflammation. Interestingly, activation of the innate immune system through 
TLRs (33) or NLRs (31) may also result in an efficient antitumor response, 
further underlining the potential of these molecules in the field of 
immunotherapy (34). 
 
 
 
Figure 6. Putative model of the function of the inflammasome in T cell priming. DNFB-induced 
inflammasome activity results in the secretion of active IL-1β, which drives the expression of IL-6 and IL-
12, thus creating an environment favoring Th1 development and thwarting Treg countereffects. Hence, 
DNFB provided at the same time a danger signal and a suitable Ag, whereas DNTB provides only an 
Ag. In the absence of danger signals, tolerance is the default pathway, relying on the low levels of IL-6 
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to stimulate Tregs. Modulation of the danger-signaling pathway can be achieved at the inflammasome 
level (negative: ASC deficiency, zYVAD; positive: SDS) or at the cytokine level (negative: IL-1Ra, anti-
IL-12; positive: IL-1β and IL-12). 
 
We also provide evidence that activation of the inflammasome results 
in the secretion of cytokines likely to favor the development of a Th1 and Th17 
response counterbalancing Treg activity and tolerance. Indeed, IL-12 is 
known to drive T cells toward a Th1 phenotype, while IL-6 favors Th17 over 
Treg development (26, 27). Th17 secrete IL-17, which further decreases the 
activity of formerly arisen Treg cells (26, 27). Finally, decreasing IL-10 levels, 
a cytokine that can counterbalance the effect of IL-12 may further tip the 
balance in the favor of the Th1 (28). These results are in accord with a recent 
study showing that IL-1β breaks tolerance by favoring the expansion of 
CD25+ effector cells (35). 
Finally, our results may shed some light on the controversy regarding 
the sensitizing potential of DNTB. Indeed, unlike several reports, including the 
present work, some authors did not observe tolerance to DNTB but a weaker 
sensitization, concomitant with dendritic cell accumulation in regional lymph 
nodes (17, 18). We propose that the frontier between tolerance and 
sensitization is narrow and easily crossed. Indeed, in conditions where DNTB 
is found to induce tolerance, we found that adding danger signals turns DNTB 
into a sensitizer. It is likely that the nature of the vehicle, the concentration of 
the molecule, and skin-preparation such as shaving will tip the balance toward 
sensitization. In conditions where DNTB is a sensitizer, it induces similar 
levels of proliferation by draining lymph node cells such as DNCB, but fails to 
induce LC migration (36), suggesting the possible recruitment of dermal DC 
by DNTB (37). We propose that DNTB fails to activate the inflammasome and 
IL-1β activation, which is crucial for LC migration, but does activate other 
molecular pathways that may, depending on the context, be sufficient to 
trigger an efficient immune response and result in sensitization. We are 
currently generating LC-specific IL-1β and ASC-deficient mice to study this 
hypothesis. Interestingly, we have conducted experiments that indicate that 
the presence of an intact inflammasome is essential for DNFB and DNCB-
induced LC migration (data not shown). Additional experiments are 
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necessary, including a characterization of the role of the inflammasome on 
dermal DC, as the exact role of both cell types in CHS remains controversial 
(38 – 41). Finally, the CHS outcome may also depend on the viral and 
bacterial environment of the host, as TLR and NLR activate similar targets 
such as NF-kB and IL-12. 
Although NLR discovery is recent, several therapeutic tools targeting 
their signaling pathways or downstream targets are already available. For 
example, down-modulation of the inflammasome has been achieved 
successfully in patients suffering from autoinflammatory disorders, either by 
blocking caspase-1 or IL-1β signaling (42–44). Additional tools will soon be 
added to this list, including anti-IL-1b, anti-IL-6, and anti-IL12/23 Abs. As for 
NLR activation, Freund’s adjuvant has been used extensively in vaccination 
studies (3, 8). We believe that gathering further insights into the role of each 
member of this large family will increase the number of patients benefiting 
from this therapeutic advance and will lead to the development of even more 
potent and specific drugs. 
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Materials and Methods 
 
Cell culture and stimulation 
Primary keratinocytes (human epidermal keratinocytes (Biocoba), were 
cultured in Epilife medium supplemented with Human Keratinocyte Growth 
Supplement (Biocoba) and 60 µM of Ca2+. HaCaT cells were cultured in 
DMEM: F-12 medium (1/1) (Invitrogen) supplemented with 5 µg/ml human 
insulin, 10 ng/ml cholera toxin, 0.4 µg/ml hydrocortisone, 10 ng/ml human 
epidermal growth factor, and 10% FCS. Cell cultures were maintained at 37°C 
in humidified incubators with 5% CO2. Primary keratinocytes were pretreated 
with 0.1 ng/ml hTNF (Alexis) for 6 h, and stimulated with TNCB (0.5–10 µg/ml) 
(Fluka), DNCB (0.5–10 µg/ml), DNFB (0.5–10 µg/ml) (Fluka), DNTB 
(Lancaster Synthesis) (0.5–50 µg/ ml) (a gift from Ian Kimber, Faculty of Life 
Sciences, The University of Manchester, Manchester, U.K.), urushiol, (1–5 
µg/ml) and SDS (15 µg/ ml), for 24 h with or without Z-Val-Ala-Asp-
fluoromethylketone (Alexis) at 50 µM for 24 h before IL-1b secretion was 
determined by ELISA. 
 
Analysis of contact hypersensitivity and tolerance in mice 
Mice were handled according to institutional and Swiss Federal Veterinary 
Office guidelines. IL-1R and ASC-deficient mice were obtained from M. Kopf 
(Molecular Biomedicine ETHZ, Zürich-Schlieren, Switzerland) and V.M. Dixit 
(Genentech, San Francisco). For classical CHS studies: 6–7- week-old mice 
were sensitized by topical (external) applications of 20 µl of 0.5% TNCB, 
DNCB, DNFB, oxazolone, or 1% DNTB in acetone-olive oil (AOO) or AOO 
alone to the skin of the right ear at days 0 and 1. Elicitation was done at day 5 
by topical application of 20 µl of 0.3% DNCB, DNFB, oxazolone, or 1% DNTB 
in AOO to the contra-lateral ear. Ear thicknesses were measured with a digital 
thickness gauge (Mitsutoyo) before and 24 h after hapten challenge. For 
tolerance induction, mice were shaved on the belly on day -1, then treated 
with 20 µl of 0.5% DNTB or DNFB on day 0 and 1, then sensitized on the right 
ear and challenged on the left ear as described above. For adoptive transfer, 
mice were shaved on the belly on day -1, then treated with 20 ul of 0.5% 
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DNTB or DNFB on day 0 and 1, sacrificed on day 5. Single cell suspension 
from inguinal, lymph nodes and spleen were washed in DMEM medium, 
counted, concentrated, and injected in the tail vein of strain-matched naive 
mice. Alternatively, single cell suspension obtained from the lymph node and 
spleen of DNTB-treated mice were depleted of CD4+/CD25+ cells using a 
two-step magnetic sorting (AutoMACS and Treg depletion kit, Miltenyi Biotec) 
according to the manufacturer’s protocol. Recipient mice were sensitized on 
the right ear with 20 µl of 0.5% DNFB on day 1 and 2 after adoptive transfer, 
then challenged on the left ear on day 6, as described above. 
 
SDS, IL-1β, zYVAD, and IL-1R agnoist (IL-1RA) administration 
Twenty microliters of either SDS in dimethylformamide (1% w/v) or 
dimethylformamide alone was applied 30 min before each sensitization with 
DNTB. Ten microliters of either recombinant mIL-1b (BD Biosciences) in PBS 
(200 ng/ml) or PBS alone was injected s.c. in the ear 30 min before each 
sensitization with DNTB. Twenty microliters of either acyloxy-Z- Val-Ala-Asp-
chloromethylketone (Alexis) in DMSO (0.2 mM) or DMSO alone was applied 
on the right ear 30 min before sensitization with DNFB on days 0, 1, and 2. 
One hundred microliters of IL-1R antagonist (Amgen) (150 ug/ul) or PBS was 
injected i.p. twice daily for three consecutive days, starting 12 h before the 
first sensitization with DNFB. 
 
Cytokine detection by ELISA 
Supernatants from primary keratinocyte cultrures were analyzed by ELISA for 
IL-1β (BD Biosciences) according to the manufacturer’s instructions. ASC or 
wild-type littermates were treated with 20 µl of 0.3% DNFB on day 0 and 1 
were sacrificed on day 2. Single cell suspension of draining neck lymph nodes 
were obtained and cultivated in DMEM medium for 5 days. Supernatants were 
then analyzed by ELISA IL-6 (R&D Systems), IL-10 (R&D Systems), and IL-
12 (mouse IL-12/IL-23 p40 allele-specific DuoSet DY499, BD Biosciences) 
according to the manufacturer’s instructions. 
Statistical analysis Groups were compared using one-tailed Student’s or 
Aspin-Welch’s t tests. 
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Abstract 
 
 
 
The NLRP3 inflammasome initiates inflammation upon sensing 
pathogen- and danger-associated molecular patterns (PAMPs/DAMPs) by 
regulating the secretion of caspase-1 dependent cytokines including 
interleukin (IL)-1β. How a wide variety of structurally distinct PAMPs and 
DAMPs trigger NLRP3 inflammasome activation at a molecular level is 
largely unknown. Here we show that the mitogen activated protein kinases 
(MAPK) JNK2 in myeloid cells, and P38 in keratinocytes, are required for 
NLRP3 inflammasome activation, by linking DAMP/PAMP sensing to 
mitochondrial permeabilization and mitochondrial DNA (mtDNA) release, 
via the mobilization of Bcl-2 associated death promoter (BAD) from the 
cytosol to the mitochondrial membrane. Accordingly, pharmacological 
inhibition or genetic silencing of JNK2/P38 and/or BAD abrogates mtDNA 
release, inflammasome activation and IL-1β secretion in response to 
DAMPs and PAMPs known to trigger NLRP3 inflammasome activation. 
Phosphorylation of JNK2/P38 is required for NLRP3 inflammasome 
activation, and the latter is modulated by MAPK phosphatase 1 (MKP-1). 
Furthermore, mice deficient in JNK2 present reduced peritoneal IL-
1β production and neutrophil infiltration in a model of NLRP3-dependent 
uric acid-induced peritonitis. Thus, our results identify the MAPKs JNK2 
and P38 as crucial mediators of NLRP3 inflammasome activation by 
distinct DAMPs and PAMPs, and identify these kinases as potential targets 
for therapeutic modulation of inflammasome-driven auto-inflammatory 
diseases. 
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 Inflammasomes are intracellular multiprotein complexes that are activated 
upon cellular stress or infection and trigger the caspase-1-dependent processing 
of pro-inflammatory cytokines such as IL-1β. Inflammasomes are involved in  
acquired inflammatory diseases such as gout (1) and is the cause of hereditary 
autoinflammatory diseases such as the cryopyrin-associated periodic syndromes 
caused by activating mutations in the inflammasome component NLRP3. Key 
components of the NLRP3 inflammasome are the Nod-like receptor (NLR) 
NLRP3, the adaptor protein ASC and caspase-1. NLRP3 inflammasome 
activators include the DAMPs monosodic uric acid (MSU), alum, silica and ATP 
as well as the PAMPs nigericin, zymosan, and alpha-toxin of S. aureus (2). Upon 
detection of such varied PAMPs and DAMPs, NLRP3 recruits the adaptor protein 
ASC and procaspase-1, which results in caspase-1 activation and processing of 
cytoplasmic targets including the pro-inflammatory cytokines IL-1β and IL-18 (3).  
 
The mechanisms leading to NLRP3 inflammasome activation are intensely 
debated, and there is currently no evidence that NLRP3 binds directly to any of 
its known activators. The diversity of structure in potential ligands suggests a 
shared mechanism that integrates signals generated by PAMPs and DAMPs to a 
common pathway leading to NLRP3 oligomerization and inflammasome 
activation. To date three distinct mechanisms have been proposed to account for 
NLRP3 activation, namely the generation of mitochondria-derived reactive 
oxygen species (ROS), cellular potassium efflux, and phagolysosomal 
destabilization (4). Furthermore, recent data suggest that NLRP3 inflammasome 
activation is a consequence of direct binding of oxidized mitochondrial DNA to 
NLRP3, or binding of the phosphorylated double-stranded RNA-dependent 
protein kinase PKR to NLRP3 (5,6). A unifying mechanism linking PAMP/DAMP 
signaling to inflammasome activation is unknown to date.  
 
MAPK regulate important cellular functions including proliferation, 
differentiation and survival by linking extracellular signals to intracellular 
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responses (7). MAPK pathways also coordinate and integrate cellular responses 
to PAMPs and DAMPs, and deregulation of MAPK activity is associated with 
immune disorders (7,8). We therefore sought to investigate whether MAPK 
pathways may be involved in, or regulate inflammasome activation. 
 
Our first approach consisted in a pharmacological inhibition of the 
conventional MAPK JNK, P38 and ERK. Mouse bone marrow-derived dendritic 
cells (BMDCs) were pre-stimulated with ultra-pure LPS, which induces NF-kb 
dependent pro-IL-1β synthesis, then incubated with selective MAPK inhibitors 
prior to exposure to known NLRP3 inflammasome activators. A significant 
reduction of IL-1β 
secretion was obtained with the JNK inhibitor SP600125 being comparable to the
one observed with the caspase inhibitor ZVAD (Fig.1a,b). The P38 and ERK inhi
bitors 2-(4-Chlorophenyl)-4-(4-fluorophenyl)-5-pyridin-4-yl-1,2-dihydropyrazol-3-
one and U0126, respectively, failed to show significant similar inhibition in this 
experimental setting (Fig.1a,b). In line with this, exposure of BMDCs to 
inflammasome activators led to JNK, mainly JNK2 phosphorylation, at similar or 
higher levels to those induced by antimycin and anisomycin, two known inducers 
of MAPK activation (Fig.1c). 
To determine which isoform of JNK is involved in IL-1β  secretion and 
exclude off-target effects, we specifically silenced the expression of either JNK1 
or JNK2, the two JNK isoforms present in myeloid cells, using shRNA (suppl. 
Fig.5). JNK2 knock-down THP-1 macrophages showed reduced IL-1β  secretion 
when stimulated with NLRP3 inflammasome activators, whereas silencing of 
JNK1 did not significantly affect IL-1β secretion (Fig.1d,e). Similar results were 
obtained when cells were stimulated with polydA:dT, an AIM2 inflammasome 
activator (9) (suppl. Fig.1), suggesting that JNK2 is involved in both NLRP3 and 
AIM2 inflammasome activation. 
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Figure.1: MAPK are involved in inflammasome activation 
a,b, BMDCs were pulsed with upLPS then treated with JNK, P38 or ERK inhibitors or the caspase inhibitor 
ZVAD prior exposure to NLRP3 inflammasome activators. Supernatants were collected after 6h and IL-1β 
was analyzed by ELISA (a) and Western blot (b). c, BMDCs pulsed with upLPS were exposed to NLRP3 
inflammasome activators and anisomycin and IL-1β was analyzed in cell lysate after 30min by Western blot 
as indicated. d,e, THP-1 macrophages stably expressing shRNA to caspase-1, JNK1 or JNK2 were 
differentiated with PMA or upLPS and exposed to MSU, nigericin and alum. Supernatants were collected 
after 6hrs and IL-1β was analyzed by ELISA (d) and Western blot (e) as cell lysates. f, THP-1 macrophages 
stably expressing shRNA to JNK1 or JNK2 were differentiated with PMA or upLPS and exposed to heat-
killed listeria monocytogenes (HKLM), IL-1β and TNF-α were analyzed in supernatants after 12hrs by 
ELISA. g, human primary keratinocytes were treated with JNK, P38 or ERK inhibitor or the caspase inhibitor 
ZVAD prior to UVB irradiation. IL-1β was analyzed in supernatants by ELISA. h, human primary 
keratinocytes transiently expressing siRNA against caspase-1, P38α, β, γ and δ were UVB irradiated and IL-
1β was analyzed in supernatants after 6hrs by ELISA. i, human primary keratinocytes were irradiated with 
UVB, and phosphoP38, total P38 and β-actin protein levels were analyzed in cell lysate by Western blot. 
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This effect was neither due to decreased pro-IL-1β synthesis nor to the down-
regulation of inflammasome components (suppl. Fig.6, Fig.1e), nor to a general 
immunosuppressive effect, since TNF-α (Fig.1f) and IL-8 (suppl. Fig.4) were 
normally secreted despite JNK2 knock-down. In accordance with the above, 
peritoneal macrophages from JNK2-/- mice also showed reduced secretion of IL-
1β (suppl. Fig.8). 
To determine if MAPK signaling is also involved in the regulation of IL-1β 
secretion in non-myeloid cells, keratinocytes were incubated with MAPK 
inhibitors prior to NLRP3 inflammasome activation with UVB, or AIM2 
inflammasome activation with polydA:dT. Remarkably, the P38 inhibitor 2-(4-
Chlorophenyl)-4-(4-fluorophenyl)-5-pyridin-4-yl-1,2-dihydropyrazol-3-one 
significantly reduced IL-1β secretion to a similar extent as the caspase inhibitor 
ZVAD (Fig.1g), and 2-AP a double-stranded RNA-dependent protein kinase 
(PKR) inhibitor (suppl. Fig.2), recently shown to be involved in inflammasome 
activation (6). Furthermore, exposure of keratinocytes to UVB resulted in a rapid 
increase of phosphorylated P38 (Fig.1i), and selective silencing of distinct P38 
isoforms with siRNA (suppl. Fig. 7), demonstrated that the the α and δ isoforms   
but not the  β and γ P38 isoforms are required for IL-1β secretion in UVB-
irradiated (Fig.1h) and polydA:dT-transfected keratinocytes (suppl. Fig. 3).  
To confirm the involvement of JNK in inflammasome activation, upLPS-
pulsed BMDCs were exposed to the JNK activator anisomycin alone. This 
resulted in IL-1β secretion at levels similar to that induced by zymosan (Fig. 2a). 
In addition, overexpression of an active form of JNK2, but not JNK1, in J774.1 
macrophages also resulted in spontaneous secretion of IL-1β ( (Fig. 2b), 
whereas overexpression of a dominant negative JNK2, but not JNK1, reduced IL-
1β secretion in the same cells stimulated with zymosan (Fig. 2c).  
It has been recently proposed that mitochondrial loss of membrane 
potential and leakage of mtDNA to the cytosol are crucial events for NLRP3  
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Figure 2: JNK mediates mitochondrial damage.   a, BMDCs upLPS pulsed were exposed to zymosan 
and anisomycin. IL-1β was analyzed in supernatants after 6hrs by ELISA. b, J774.1 macrophages 
transiently overexpressing active JNK1 and active JNK2 were pulsed with upLPS and supernatants were 
collected after overnight incubation and IL-1β measured by ELISA. c, J774.1 macrophages  transiently 
overexpressing JNK1, dominant mutant JNK1 (JNK1apf), JNK2 and dominant mutant JNK2 (JNK2apf) were 
pulsed with upLPS and exposed to zymosan. IL-1β was analyzed in supernatants by ELISA after 6hrs. d, 
THP-1 macrophages stably expressing shRNA to JNK2 were exposed to MSU for the indicated time points, 
and mitotracker green/deep red double positive cells are shown. e, THP-1 macrophages stably expressing 
shRNA to JNK2 were exposed to MSU for the indicated time points and mitochondrial DNA in purified 
cytosolic fractions were analyzed by quantitative PCR. f, Purified mitochondrial and cytosolic fractions from 
monocytes treated with the indicated inflammasome activators were analyzed by western blotting using 
antibodies to JNK, BAD and pBCL-XL. g,  Human primary keratinocytes were UVB irradiated, stained with 
mitotracker deep red and anti-BAD and analyzed by confocal microscopy. 
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inflammasome activation (5,10,11). To assess the impact of MAPK signaling on 
these events, we measured mitochondrial membrane potential (ΔΨm), and 
analyzed the presence of mtDNA in the cytosol of THP-1 macrophages prior to, 
or 30min and one hour after exposure to MSU. In contrast to mock-transfected 
THP-1, JNK2 knock-down cells showed barely any sharp loss of ΔΨm (Fig. 2d), 
and virtually no cytosolic mtDNA leakage (Fig. 2e). It has been reported that JNK 
translocation into the mitochondria can occur upon cell stress (12,13). Analysis of 
the purified mitochondrial fraction of monocytes exposed to different NLRP3 
inflammasome activators revealed significantly enhanced JNK2, but not JNK1 
content in the mitochondrial fraction, suggesting that migration of JNK2 from the 
cytoplasma to the mitochondria is an early event in inflammasome activation 
(Fig. 2f). 
The mechanism leading to mtDNA leakage that has been reported to be 
associated with NLRP3 inflammasome activation is currently unclear (5). 
Experimental evidence suggests that JNK can regulate the mitochondrial 
permeability transition by interacting with BCL-2 family members (14,15). 
Interestingly, BCL-2 overexpression was reported to negatively regulate NLRP3 
inflammasome activation via ΔΨm modulation (5). To investigate if other BCL-2 
members are involved in this process, we analyzed the presence of these 
proteins in the purified mitochondrial fraction of monocytes exposed to NLRP3 
inflammasome activators. We found that NLRP3 inflammasome activation is 
associated with BAD translocation to the mitochondria, but not the translocation 
of BCL-XL (Fig. 2f, In accordance with this, using confocal microscopy, we 
demonstrate migration of BAD to the mitochondria after UVB irradiation in 
keratinocytes (Fig. 2g). 
To functionally assess if BCL2 members are critical for inflammasome 
activation, we knocked down BAD, BCL-XL, BIM, and BAX in THP1 
macrophages with shRNA. Secretion of IL-1b following MSU, nigericin and alum 
exposure was significantly reduced in BAD, BCL-XL and BAX but not BIM knock-
down cells (Fig. 3a,b). In contrast, TNF-α and IL-8 were not affected by BAD, 
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BCL-XL or BAX knock-down (Ffig. 3c and suppl. Fig. 9). Similar results were 
observed when BAD, BCL-XL and BAX were silenced in UVB-irradiated human 
keratinocytes (suppl. Fig. 10), or THP-1 macrophages and keratinocytes exposed 
to polydA:dT (suppl. Fig. 11,12), suggesting that BAD, BCL-XL and BAX are 
required for NLRP3 and AIM2 inflammasome activation. Flow cytometry analysis 
of THP-1 macrophages exposed to MSU with mitotracker deepRed revealed a 
significant reduction in the loss of ΔΨm when BAD, BCL-XL and BAX were 
silenced (Fig. 3d), and the latter correlated with reduced mtDNA leakage into the 
cytosol (Fig. 3e). Taken together, these results provide evidence that the BCL2 
family members BAD, BCL-XL and BAX are involved in the mitochondrial 
leakage occurring upon exposure to inflammasome activators, and this process 
is distinct from apoptosis, as revealed by the absence of detectable caspase-3 
activity under these conditions (suppl. Fig. 13). 
To further establish the involvement of BAD in inflammasome activation, 
we incubated upLPS-pulsed BMDCs with ABT-737, a BAD mimetic not able to 
induce apoptosis by itself (16). In the absence of exposure to PAMPs and 
DAMPs, ABT-737 induced slight IL-1β secretion, and this was further enhanced 
by combination with the JNK activator anisomycin (Fig. 3f). Thus, artificially 
mimicking a situation in which JNK and BAD are activated is sufficient for 
triggering inflammasome activation in the absence of PAMPs and DAMPs. In 
accordance with a key role for BAD in inflammasome activation, we could detect 
spontaneous secretion of IL-1β in J774.1 macrophages upon forced 
overexpression of BAD (Fig. 3g). Likewise, when the scaffold protein 14-3-3, also 
termed YWHAQ which is known to sequestrate BAD to the cytosol and prevent 
its mitochondrial translocation (17), was overexpressed, IL-1β secretion in  J774.1 
macrophages upon zymosan exposure was significantly reduced (Fig. 3h).  
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Figure 3: BCL-2 family members are involved in inflammasome activation and mitochondrial damage 
a,b, THP1 macrophages stably expressing shRNA against caspase-1, BIM, BAD, BAX and BCL-XL were 
differentiated with PMA or upLPS and exposed to the indicated inflammasome activators. IL-1β was 
analyzed in supernatants by ELISA and Western blot and in cell lysates by Western blot.  c, THP1 
macrophages stably expressing shRNA to BAD, BAX and BCL-XL were differentiated with PMA or upLPS 
and exposed to heat killed listeria monocytogenes (HKLM). IL-1β and TNF-α were analyzed in supernatants 
12hrs after exposure by ELISA. d, THP1 macrophages stably expressing shRNA against BAD, BAX and 
BCL-XL were exposed to MSU for the indicated time points. Mitotracker green/deep red double positive cells 
are shown. e, THP-1 macrophages  stably expressing shRNA to BAD, BAX and BCL-XL were exposed to 
MSU for the indicated time points and mitochondrial DNA from purified cytosolic fractions was analyzed by 
quantitative PCR. f, upLPS pulsed BMDCs were incubated with anisomycin with or without the BAD mimetic 
abt737. IL-1β was analyzed in supernatants after 6hrs. g, J774.1 cells transiently overexpressing BAD or 
YWHAQ were pulsed with upLPS and IL-1β was analyzed in supernatants by ELISA after overnight 
incubation. h, J774.1 macrophages transiently overexpressing BAD or YWHAQ were pulsed with upLPS 
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and exposed to zymosan. IL-1β was measured in supernatants after 6hrs. i, Purified mitochondrial and 
cytosolic fractions from THP-1 macrophages stably expressing the indicated shRNA and exposed to 
nigericin were analyzed by Western blot. j, Purified mitochondrial fractions from monocytes exposed to 
nigericin were co-immuno-precipitated with antibodies to BAD and BCL-XL and analyzed by Western blot. 
 
Given the evidence that JNK2 phosphorylation in myeloid cells, or P38 
phosphorylation in keratinocytes, as well as BAD translocation to the 
mitochondria in both cell types are prerequisites for inflammasome activation, we 
subsequently investigated the possible link between JNK activation and BAD 
translocation. To this end, purified mitochondrial fractions of shRNA knock-down 
THP1 macrophages exposed to the inflammasome activator nigericin were 
analyzed. We demonstrated that BAD translocates to the mitochondria upon 
inflammasome activation, but this effect was decreased in JNK2 and BCL-XL 
knock-down (Fig. 3i). The association of BAD with BCL-XL in the mitochondria is 
an important event in the loss of ΔΨm (18). By immuno-precipitating BAD and 
BCL-XL from the purified mitochondrial fraction of monocytes after incubation 
with nigericin, we demonstrated that BAD and BCL-XL directly interacted upon 
inflammasome activation (Fig. 3j).  
JNK and P38 kinases can be dephosphorylated and thus inactivated by 
MKP-1, also termed DUSP1. This phosphatase has been shown to suppress the 
production of pro-inflammatory cytokines as evidenced by increased 
inflammation and impaired bacterial clearance in MKP-1-/- mice (19-21). Following 
exposure of peritoneal macrophages from MKP-1-/- mice to NLRP3 
inflammasome activators, significantly higher amounts of IL-1β secretion were 
detected (Fig. 4a), and this correlated with higher amounts of phosphorylated 
JNK 1 and 2. (Fig. 4b). Conversely, overexpression of MKP-1 in J774.1 
macrophages exposed to the NLRP3 inflammasome activator zymosan, resulted 
in a significant reduction in IL-1β when compared to mock-transfected cells (Fig. 
4c).   
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Figure 4: MKP-1 modulates NLRP3 inflammasome activation and JNK2 is required for IL-1β secretion 
in vivo 
a, upLPS-pulsed BMDCs from WT and MKP-1 mice were exposed to the indicated inflammasome 
activators. IL-1β was analyzed in supernatant after 6hrs by ELISA.  b, Total JNK (tJNK) and phospho-JNK 
(pJNK) in lysates of upLPS-pulsed BMDC from WT and MKP-1 mice were analysed by Western blot. c, 
J774.1 macrophages transiently overexpressing MKP-1 were pulsed with upLPS and exposed to zymosan. 
IL-1β was analyzed in supernatants after 6hrs by ELISA. d, e, Mice received MSU intraperitoneally and after 
6hrs peritoneal lavage was collected, neutrophils were analyzed by flow cytometry and IL-1β was measured 
by ELISA. f, Hypothetical model of inflammasome activation. 
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To determine if the MAPK JNK2 regulates NLRP3-inflammasome 
activation and inflammation in an in vivo setting, JNK2-deficient and WT mice 
were injected intraperitoneally with MSU, causing NLRP3-dependent peritonitis 
as previously reported (22). Peritoneal lavage performed after 6 hours revealed 
significantly reduced levels of IL-
1β and neutrophil infiltration in JNK2-deficient mice which was comparable to the 
reduction in peritoneal IL-1β and neutrophil infiltration observed in mice deficient 
in inflammasome components ASC and NLRP3 (Fig. 4d,e). 
 
Taken together, our data reveal a novel role for the MAPKs JNK2 and P38 
and to BAD in inflammasome activation and unravel an unexpected molecular 
pathway linking DAMPs and PAMPs to mitochondrial permeabilization, mtDNA 
release and subsequent inflammasome activation. The release of mtDNA into the 
cytosol is a key event preceding inflammasome activation, and this process is 
driven by the above MAPK which when phosphorylated interact with the Bcl-2 
family members Bad and Bcl-xL that are likely the essential mediators causing 
the disruption of mitochondrial integrity (Fig. 4f). Specifically designing 
therapeutics targeting JNK2, P38 and BAD may provide new avenues for 
selective inhibition of inflammasome activity and therapy of autoinflammatory 
diseases (23).  
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Figure S1: Gene Silencing of JNK2 decreases IL-1β secretion in myeloid cells. THP-1 transfected with 
shRNA against above genes were differentiated with PMA, pulsed with upLPS and then stimulated with 
PolydA:dT. Supernatants were analyzed 24h after stimulation by ELISA for IL-1β secretion. Figure is 
representative of three independent experiments. Statistical significance was determined by Student’s t-test.  
 
 
 
Figure S2: P38 inhibitor decreases IL-1β secretion. HKCs were pre-treated with ZVAD, 2-AP or P38 
inhibitor prior exposure with PolydA:dT. Supernatants were analyzed 24h after stimulation by ELISA for IL-
1β secretion. Figure is representative of three independent experiments. Statistical significance was 
determined by Student’s t-test.  
 
Poly dA:dT
sh
MO
CK
sh
Ca
sp
-1
sh
JN
K1
sh
JN
K2
0
1500
3000 P = n.s.
P < 0.0001
P < 0.0001
IL
-1
β 
(p
g/
m
l)
Poly dA:dT
MO
CK
ZV
AD 2-A
P
P3
8 i
nh
.
0
200
400 P < 0.0001
IL
-1
β 
(p
g/
m
l)
101	  	  
 
Figure S3: Gene Silencing of P38 decreases IL-1b secretion in keratinocytes.  HKCs transfected with 
siRNA against above genes were exposed to PolydA:dT. Supernatants were analyzed 24h after stimulation 
by ELISA for IL-1β secretion. Figure is representative of three independent experiments. Statistical 
significance was determined by Student’s t-test.  
   
  
Figure S4: Gene Silencing of JNK does not impair secretion of other cytokines. THP-1 transfected with 
shRNA against above genes were differentiated with PMA, pulsed with upLPS and then stimulated with heat 
killed Listeria monocytogenes or heat killed Escherichia coli. Supernatants were analyzed 24h after 
stimulation by ELISA for IL-8 secretion. Figure is representative of three independent experiments.  
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Figure S5: Knock down efficacy of stably transfected shRNA THP1 macrophages. Total cell lysates of 
THP-1 macrophages transfected with shRNA against above genes were analyzed by western-blot. 
 
  
 
Figure S6: IL-1β and IL-18 expression in stably transfected THP-1 macrophages. THP-1 transfected 
with shRNA against above genes were differentiated with PMA, pulsed with upLPS and real time pcr was 
performed for the above genes. 
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Figure S7: Knock Down efficiency in transiently expressing siRNA Primary Human Keratinocytes. 
Total cell lysates of primary keratinocytes transfected with siRNA against above genes were analyzed by 
western-blot. 
 
 
      
Figure S8: JNK2 KO myeloid cells have impaired IL-1β secretion. BMDCs from WT and JNK2 KO mice 
were pulsed with upLPS and then stimulated with several NLRP3 inflammasome activators. Supernatants 
were analyzed 6h after stimulation by ELISA for IL-1β secretion. Figure is representative of three 
independent experiments. Statistical significance was determined by Student’s t-test.  
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Figure S9: Gene Silencing of BCL2 family members does not impair secretion of other cytokines. 
THP-1 transfected with shRNA against above genes were differentiated with PMA, pulsed with upLPS and 
then stimulated with heat killed Listeria monocytogenes or heat killed Escherichia coli. Supernatants were 
analyzed 24h after stimulation by ELISA for IL-8 secretion. Figure is representative of three independent 
experiments.  
 
Figure S10: Gene Silencing of BCL-2 family members decreases IL-1β secretion in keratinocytes. 
Keratinocytes transiently transfected with siRNA against above genes were UVB irradiated. Supernatants 
were analyzed 6h after irradiation by ELISA for IL-1β secretion. Figure is representative of three 
independent experiments. Statistical significance was determined by Student’s t-test.  
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Figure S11: Gene Silencing of BCL-2 family members decreases IL-1β secretion in myeloid cells. 
THP-1 transfected with shRNA against above genes were differentiated with PMA, pulsed with upLPS and 
then stimulated with PolydA:dT. Supernatants were analyzed 24h after stimulation by ELISA for IL-1β 
secretion. Figure is representative of three independent experiments. Statistical significance was determined 
by Student’s t-test.  
  
Figure S12: Gene Silencing of BCL2 family members decreases IL-1β secretion in keratinocytes.  
HKCs transfected with siRNA against above genes exposed to PolydA:dT. Supernatants were analyzed 24h 
after stimulation by ELISA for IL-1β secretion. Figure is representative of three independent experiments. 
Statistical significance was determined by Student’s t-test.  
 
 
Poly dA:dT
sh
MO
CK
sh
Ca
sp
-1
sh
BA
D
sh
BA
X
sh
BC
L-X
L
0
1500
3000
P < 0.0001
P < 0.0001
P < 0.0001
P < 0.0001
IL
-1
β 
(p
g/
m
l)
Poly dA:dT
siM
OC
K
siC
as
p-1
siB
ID
siB
AD
siB
AX
siB
CL
-X
L
0
200
400 P = n.s.
P < 0.0001
P = 0.0008
P < 0.0003
IL
-1
β 
(p
g/
m
l)
106	  
 
Figure S13: Inflammasome activation does not lead to apoptosis. THP-1 macrophages differentiated 
with PMA, pulsed with upLPS and then stimulated with MSU (150ug/mL) or staurosporine for 6h. Cell 
lysates were analyzed by western-blot. Figure is representative of two independent experiments.  
 
 
 
Figure S14: JNK inhibitor decreases MSU induced peritonitis. Mice were treated i.p. with JNK inhibitor 
3mg/kg 30min prior i.p. injection of MSU. Six hours after exposition to MSU, peritoneal lavage was analized 
by FACS. Figure is representative of three independent experiments. Statistical significance was determined 
by Student’s t-test.  
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Methods 
 
Mice 
Nlrp3−/−, Asc−/− mice were described previously24,25,.JNK1−/−, JNK2−/− were 
obtained from Jackson Laboratories, MKP-1−/−, gift from Prof. Kato, Toxicology 
Department, KIT, Germany. All mice were on a C57BL/6 background. 
Cell fractionation 
Mitochondrial and cytosolic fractions were isolated from monocytes or PMA-
differentiated THP1 cells as previously described26. 
Reagents 
Nigericin, rotenone, anisomycin,antimycin, uric acid, ATP, poly(dA:dT) and silica 
were purchased from Sigma. MitoSOX, Mitotracker green, Mitotracker deep red 
were from Invitrogen. LDH release kits were from Promega. Ultrapure LPS, 
Zymosan and R837 were obtained from Invivogen. Inject alum was from Pierce. 
Anti-human an anti-mouse IL-1β antibodies were from R&D. The anti-NLRP3 
antibodies (Cryo-2) were from Adipogen. Anti-caspase-3, BAD, BCL-XL, BAX, 
BIM, COXIV, JNK, pJNK, P38, YWHAQ,  anti-VDAC1 (4866) antibodies were 
purchased from Cell Signaling. Anti-ASC antibody (AL177) was from Adipogen. 
Anti-human caspase-1 (sc-622) were from Santa Cruz. Anti-phosphoP38 was 
from Abcam. All tissue culture reagents were from Invitrogen. 
Cell preparation and stimulation 
Human THP1 cells were cultured in RPMI 1640 media, supplemented with 10% 
FBS. THP1 cells were differentiated for 3  days  with 100  nM phorbol-12-
myristate-13-acetate (PMA) and primed with 100  ng  ml−1 ultra-pure LPS ON . 
Bone marrow macrophages were derived from tibia and femoral bone marrow 
progenitors as described27, and were primed for ON with 100  ng  ml−1 Ultra-pure 
LPS. For the induction of inflammasome activation, 106 LPS-primed bone 
marrow macrophages or PMA-differentiated THP1 cells plated in 12-well plates 
were treated with MSU (150  µg  ml−1), nigericin (15  µM), alum (200  µg  ml−1), silica 
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(200  µg  ml−1), R837 (15  µg  ml−1) for 6  h or with ATP (5  mM) for 30 min. For 
poly(dA:dT) transfection, poly(dA:dT) was transfected using Lipofectamine 
(4  µl  ml−1) as per the manufacturer’s protocol (Invitrogen). Cell extracts and 
precipitated supernatants were analysed by immunoblot. 
Generation of stable THP1 cells expressing shRNA 
THP1 cells stably expressing shRNA were obtained as previously described27; 
shRNA against caspase-1 plasmids has been described28 and shRNA plasmids 
against BAD, BCL-XL, BAX, YWHAQ, JNK1,2 were from Sigma. 
Generation of  human primary keratinocytes transiently expressing SiRNA  
Human primary keratinocytes were transfected using INTERFERIN, following 
manufacturer instructions with 10nM of SiRNA. All SiRNA were from sigma. 
Transient transfection of mouse macrophage cell line  
J774.1 cells were transfected with 5µg of plasmids and Lipofectamine,  following 
manufactorer instructions. All plasmids were from AddGene. 
Confocal microscopy 
Human primary keratinocytes on coverslips for 3  days and then used for 
stimulation or staining with Mitotracker deep red (50  nM). After washing two times 
with PBST, the cells were fixed with PFA 4% in PBS for 15  min and then washed 
three times with PBST. After permeabilization with Triton X-100 and blocking with 
10% goat serum in PBS, cells were incubated with primary antibodies (in 10% 
goat serum) at RT for one houre. After washing with PBST, cells were incubated 
with secondary antibodies (Invitrogen) in 10% goat serum-PBS for 60  min and 
rinsed in PBST. Confocal microscopy analyses were carried out using a Leica 
SP5. 
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Flow cytometric analyses 
Mitochondrial mass was measured by fluorescence levels upon staining with 
Mitotracker green and Mitotracker deep red at 50  nM for 30  min at 37  °C. 
Mitochondria membrane potential was measured using the kit from Invitrogen 
and performed according to the manufacturer’s instructions. Cells were then 
washed with PBS solution and re-suspended in cold PBS solution containing 1% 
FBS for FACS analysis. 
ELISA 
Cell culture supernatants were assayed for mouse and human IL-1β, IL-8 and 
TNF-α  and mouse-IL1b (R&D) according to manufacturer’s instructions. 
Statistical analyses 
All values were expressed as the mean  ±  s.e.m. of individual samples. Samples 
were analysed using unpaired Student’s t-test. 
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Chapter 6 
 
 
Conclusions and Outlook 
 
 
During the last decade great progress has been made in understanding 
the molecular and cellular mechanisms underlying the initiation of 
inflammatory responses, both beneficial and/or detrimental. Excessive 
inflammation is a critical detrimental factor in several inflammatory and 
autoimmune disorders, neurodegenerative conditions, infections, 
cardiovascular diseases, cerebral ischemia, reperfusion injury, trauma and 
cancer1. A strong link between inflammation and metabolism is becoming 
increasingly evident and several recent studies have implicated activation of 
the NLRP3-inflammasome in a variety of metabolic diseases including 
obesity, atherosclerosis and type-2 diabetes2,3. 
 
Among cytokines that have proven essential at the onset of 
inflammation and during the course of an innate immune response is the pro-
inflammatory cytokine IL-1β. This cytokine plays a fundamental role in 
regulating systemic but also certain cutaneous inflammatory responses. Since 
IL-1β is a very potent pro-inflammatory cytokine, acting locally at extremely 
low concentrations, and an excess of IL-1β production may have detrimental 
effects, the activity of the inflammasomes has to be tightly regulated. The 
mechanisms of such a regulation remain incompletely understood. Recently 
acquired knowledge regarding the processing and activation of IL-1β has 
taught us that it is implicated in the pathogenesis of an emerging family of 
autoinflammatory diseases and fever syndromes4,5. 
 
Various danger signals activate the NLRP3 inflammasome. These 
include whole pathogens, pathogen-associated molecular patterns (PAMPs), 
pathogen-associated molecules (such as bacterial pore-forming toxins and 
the malaria parasite product haemozoin), environmental irritants (such as 
	   114	  
asbestos and UVB irradiation) and damage-associated molecular patterns 
(DAMPS). The mechanisms by which these structurally distinct molecules 
trigger NLRP3 oligomerization and inflammasome activation are currently 
unclear and have been intensely debated in recent literature6-15. However, all 
of the proposed models agree that cytoplasmic K+ concentration crucially 
affects inflammasome activation. A second proposal suggests that reactive 
oxygen species (ROS) account for Nlrp3 activation. This notion is based on 
the observation that all Nlrp3-activating molecules, such as ATP, nigericin, 
alum, and uric acid, induce ROS production in macrophages and monocytes. 
A third model proposes that phagosomal destabilization and cytosolic release 
of lysosomal cathepsins drive Nlrp3 activation15 Phagocytosis of crystalline 
and particulate molecules may cause damage to the lysosomal membrane, 
which consequently leads to leakage of lysosomal cathepsins into the cytosol. 
Furthermore, oxidized mitochondrial DNA was proposed as a direct NRLP3 
ligand, being released in the cytosol after mitochondrial damage16-18. 
Intracellular calcium concentration was also proposed as a novel mechanism 
involved in NLRP3 activation7. Noteworthy, none of the direct NLRP3 
inflammasome activators was shown to be direct ligands of NLRP3. 
 
The present work was aimed at further deciphering the complex 
mechanisms involved in the sensing of danger by the innate immune system 
in tissues resulting in IL-1β secretion, extending our understanding of the role 
of IL-1β in the skin diseases acne and contact hypersensitivity . 
 
The surprising finding reported in chapter 4 of this thesis, showing that 
IL-1β can turn an almost innocuous molecule as DNTB to a sensitizer hapten, 
and promote Th-17 differentiation in CHS could have substantial implications 
in the development of new therapies for diseases in which the immune system 
is not able to mount an appropriate response, such as cancer, for example, or 
for situations in which foreign bodies remain invisible to the immune system. 
This has also implications in is the so-called immunogenic cell death, a 
situation in which dying cells provide alarm signals to their host. Such dying 
cell-derived signals could be used in cancer treatment therapies for their 
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adjuvant properties19. Moreover, such a property of IL- 1β could help to 
understand the pathogenesis of auto-immune diseases20, where for unknown 
reasons, the immune system mounts responses against self-antigens, 
therefore triggering an inappropriate inflammation, injurious to several organs. 
 
Propionibacterium acnes is the most frequent commensal found in 
inflammatory acne lesions21-23. However, a direct role of this bacterium in the 
pathogenesis of this very common skin disease is a matter of debate. In 
chapter 3 presented in this thesis, we provide evidence that 
Propionibacterium acnes is able to activate the inflammasome upon 
internalization of the bacteria by innate immune cells, inducing reactive 
oxygen species generation, phago-lysosome disruption and leakage of 
cathepsin B. The NLRP3 inflammasome is responsible for neutrophilic 
infiltrate in vivo and the targeting of IL-1β efficiently prevented the 
inflammation induced by Propionibacterium acnes. 
Although acne vulgaris is a multifactorial complex disease, our 
observation that the NLRP3 inflammasome and subsequent IL-1β activation 
are pivotal events in the innate immune response to P. acnes is an important 
finding that may have implications in the development of new inflammatory 
agent-based therapies.  This brings the focus of the pathogenesis of acne 
back to inflammation, and provides the opportunity for the development of 
therapies which are less toxic and have less side effects than the commonly 
used systemic drugs including retinoids or antibiotics.   
 
Signal transduction in response to environmental stress is a 
fundamental process in all cells24. The mitogen-activated protein kinases 
(MAPKs) and their downstream targets are one of the essential signaling 
modules that convert environmental inputs into a plethora of cellular 
programs25,26. In chapter 5 of this thesis, we provide evidence that MAPK 
pathways control inflammasome activation, which can be modulated by MAPK 
phosphatase-1.  It is known that IL-1β activates the MAPKs JNK and P38, 
suggesting a positive feedback loop.  We observed that JNK2 is required in 
myeloid cells whereas P38 is required in keratinocytes, indicating a cell 
population specific mechanism of sensing danger. In the absence of JNK, we 
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detected less IL-1β secretion upon exposure to a broad range of 
inflammasome activators, including monosodic uric acid crystals, nigericin 
(pore forming toxin), alum (vaccine adjuvant), silica crystals, zymosan (yeast 
wall particles), imiquimod (Toll-like receptor agonist), heat-killed bacteria (E. 
coli and L. monocytogenes), ATP and lastly the JNK activator anisomycin. 
The reduced amount of IL-1β secreted upon JNK activation correlated with 
reduced loss of mitochondrial membrane potential and reduced leakage of 
mitochondrial DNA to the cytosol, considered to be, when oxidized, a direct 
ligand of NLRP3.  
Notably, we could demonstrate that BCL-2 family members, which 
have largely documented roles in cell death and emerging roles in cell 
metabolism and mitochondria physiology, also play a key role in 
inflammasome activation. We showed, in myeloid cells and keratinocytes, that 
the absence of BAD, BAX and BCL-XL led to reduced mitochondrial damage 
upon inflammasome activation accompanied by a reduced release of 
mitochondrial DNA into the cytosol. As a direct consequence of this, IL-1β 
secretion was impaired, upon stimulation with a broad range of inflammasome 
activators. 
Despite the considerable advance in our understanding of the 
regulation of inflammasome activation resulting from our discovery of the key 
role of JNK and P38, the events linking the encounter of danger and/or 
pathogens and MAPK activation still remain to be elucidated.  Notably, 
whether NLRP3 is a direct target of MAPK or if NLRP3 has other possible 
endogenous ligands (such as cytochrome c or other mitochondrial proteins) is 
not known to date. In addition to mitochondrial damage-related events, other, 
intracellular danger signals may be involved in inflammasome activation, as 
recently reported for calcium and ER stress7,27,28. The understanding of these 
mechanisms linking cell injury and inflammation could help us to understand 
the possible mechanisms involved in the pathogenesis of several auto-
immune and auto-inflammatory diseases. JNK was shown to play a very 
important role in many chronic diseases that are associated with chronic 
inflammation, as hypertension, artherosclerosis, obesity and insulin 
resistance, and classic chronic inflammatory diseases as diabetes, 
rheumatoid arthritis29-35. Recently it was suggested that the inflammation in 
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these diseases is dependent of NLRP3 inflammasome36-41. We propose that, 
among other pro-inflammatory functions, JNK has also the regulation of 
NLRP3 activation, providing novel targets for treatment of a broad range of 
diseases in which IL-1β is involved. 
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Appendix A 
 
 
Abbreviation and units 
 
 
A.1 Abbreviations 
 
ANOVA  analysis of variance 
ASC   apoptosis-associated speck-like protein containing a  
   CARD 
ATP   adenosine triphosphate 
BAD   bcl-2 associated death promoter 
BAX   bcl-2 associated X protein 
BCL-XL  b-cell lymphoma extra large protein 
BID   bh-3interacting domain death agonist 
BIM   bcl-2 interacting mediator of cell death 
BPE   bovine pituitary extract 
BSA   bovine  serum albumin 
CARD   caspase recruitment domain 
Co-IP   co-immuno precipitation 
Ctr   control   
DAP   death-associated protein 
DMSO  dimethylsulfoxide 
DNA   deoxyribonucleic acid 
ECL   enhanced chemoluminiscence 
EDTA   ethylediaminetetraacetic acid 
EGF   epidermal growth factor 
ELISA   enzyme linked immunosorbent assay 
ER   endoplasmitic reticulum 
ERK   extracellular signal regulated kinase 
FCS   fetal calf serum 
FITC   luorescein isothiocyanate 
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HRP   horseradish peroxidase 
IPAF   inflammatory protease activating factor 
IFN   interferon   
IKB   inhibitor of nuclear factor kb 
IKK   inhibitor of nuclear factor kb kinase 
IL   interleukin   
IL-1R   interleukin-1 receptor 
IL-1Ra  interleukin-1 receptor antagonist 
IP   immune precipitation 
JNK   C-Jun N-terminal Kinase 
KGF   Keratinocyte growth factor 
LB   Luria-Bertani 
LDH   lactate dehydrogenase 
LPS   lipopolysacharide 
LRR   leucine rich repeat 
MAP   mitogen activated protein 
NLRP   NACHT, LRR and PYD domains-containing protein 
NAIP   NLR family apoptosis inhibitory protein 
NFKB   nuclear factor kB 
Ns   non significant 
O/N   over night  
PCR   polymerase chain reaction 
RNA   ribonucleic acid  
RT   room temperature 
shRNA  short hairpin ribonucleic acid 
siRNA   small interference ribonucleic acid 
SDS   sodium dodecyl sulfate 
SFM   serum fee medium 
SN   supernatant 
TLR   toll-like receptor 
TNF   tumor necrosis factor 
UV   ultraviolet light 
UVB   ultraviolet B 
VEGF   vascular endothelial growth factor 
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WT   wild-type 
 
A.2 Units 
 
bp   base pairs 
°C   Celsius degrees 
cm   centimeter 
Da   Dalton  
dpi   dots per inch 
g   gram 
µg   microgram 
ng   nanogram 
pg   picogram 
h   hour 
J   Joule 
µL   microliter 
mL   milliliter 
M   molar 
uM   micromolar 
nM   nanomolar 
U   Units 
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